1 **Functional analysis across model systems implicates ribosomal proteins in**
2 **growth and proliferation defects associated with hypoplastic left heart syndrome**
3

Tanja Nielsen[1,4,*], Anaïs Kervadec[1,*], Maria A. Missinato[1], Michaela Lynott[1], Xin-Xin I.

Zeng[1], Marie Berenguer[1], Stanley M. Walls[1], Analyne Schroeder[1], Katja Birker[1], Greg

Duester[1], Paul Grossfeld[3], Timothy J. Nelson[2], Timothy M. Olson[2,], Karen Ocorr[1], Rolf

Bodmer[1], Jeanne L. Theis[2,#], Georg Vogler[1,#], Alexandre R. Colas[1,#]

[1]Development, Aging and Regeneration Program, Center for Genetic Disorders and

Aging Research, Sanford-Burnham-Prebys Medical Discovery Institute, La Jolla, CA,

USA.

[2]Cardiovascular Genetics Research, Mayo Clinic, Rochester, MN, USA.

[3]University of California San Diego, Rady Children's Hospital, San Diego, CA, USA.

[4]Department of Biochemistry, Chemistry and Pharmacy, Freie Universität Berlin, Berlin,

Germany

* These authors contributed equally

[#] Co-corresponding authors

Keywords: Congenital heart disease, HLHS, whole genome sequencing, rare variant

filtering, cardiogenesis, *Drosophila*, iPSC, zebrafish, *RPS15A*, *TP53*, *yorkie*,

tinman/NKX2-5, Dorsocross/TBX5, pannier/GATA6.

Abstract

Hypoplastic left heart syndrome (HLHS) is the most lethal congenital heart
disease (CHD). The pathogenesis of HLHS is poorly understood and due to the likely
oligogenic complexity of the disease, definitive HLHS-causing genes have not yet been
identified. Postulating that impaired cardiomyocyte proliferation as a likely important
contributing mechanism to HLHS pathogenesis, and we conducted a genome-wide
siRNA screen to identify genes affecting proliferation of human iPSC-derived
cardiomyocytes (hPSC-CMs). This yielded ribosomal protein (RP) genes as the most
prominent class of effectors of CM proliferation. In parallel, whole genome sequencing
and rare variant filtering of a cohort of 25 HLHS proband-parent trios with poor clinical
outcome revealed enrichment of rare variants of RP genes. In addition, in another
familial CHD case of HLHS proband we identified a rare, predicted-damaging promoter
variant affecting *RPS15A* that was shared between the proband and a distant relative
with CHD. Functional testing with an integrated multi-model system approach reinforced
the idea that RP genes are major regulators of cardiac growth and proliferation, thus
potentially contributing to hypoplastic phenotype observed in HLHS patients. Cardiac
knockdown (KD) of RP genes with promoter or coding variants (*RPS15A, RPS17,*
RPL26L1, RPL39, RPS15) reduced proliferation in generic hPSC-CMs and caused
malformed hearts, heart-loss or even lethality in *Drosophila*. In zebrafish, diminished
rps15a function caused reduced CM numbers, heart looping defects, or weakened
contractility, while reduced *rps17* or *rpl39* function caused reduced ventricular size or
systolic atrial dysfunction, respectively. Importantly, genetic interactions between
RPS15A and core cardiac transcription factors *TBX5* in CMs, *Drosocross, pannier* and
tinman in flies, and *tbx5* and *nkx2-7* (*nkx2-5* paralog) in fish, support a specific role for
RP genes in heart development. Furthermore, *RPS15A* KD-induced heart/CM
proliferation defects were significantly attenuated by *p53* KD in both hPSC-CMs and
zebrafish, and by Hippo activation (*YAP/yorkie* overexpression) in developing fly hearts.
Based on these findings, we conclude that RP genes play critical roles in cardiogenesis
and constitute an emerging novel class of gene candidates likely involved in HLHS and
other CHDs*.*

Introduction

Hypoplastic left heart syndrome (HLHS) accounts for 2-3% of all cases of congenital heart disease (CHD) [1, 2] and is characterized by underdevelopment of the left ventricle, mitral and aortic valves, and aortic arch [3]. HLHS has a recognized genetic component based on its familial association with left-sided obstructive congenital heart diseases [4-6]. However, segregation analyses in multiplex HLHS-CHD families [6] and genome-wide association studies (GWAS) of large cohorts [5] have lacked sufficient power to conclusively identify candidate HLHS-susceptibility genes with small to moderate effect sizes. Defects in a small number of genes involved in cardiogenesis, such as *NOTCH1* [7], *NKX2–5* [8], *MYH6* [9], and *GATA4* [8, 10] have been implicated as contributors to HLHS, as well as multiple other CHDs. However, the variety of phenotypic manifestations of HLHS, together with numerous studies linking it to diverse genetic loci [7-9, 11], suggests that HLHS is genetically heterogeneous and has a multigenic etiology [12].

It has also been hypothesized that the underdevelopment of the left ventricular myocardium includes restricted blood flow across the mitral valve and its hemodynamic effect during ventricular growth and development ("no flow – no grow" [13]), as well as endocardial defects [14]. Therefore, HLHS manifestation may be due to a combination of cardiomyocyte autonomous and non-autonomous genetic as well as mechanical effects, all of which likely affect proliferation and differentiation in the developing heart.

In a HLHS mouse model, loss of Sin3A Associated Protein 130 (*Sap130)* and the protocadherin *Pcdha9* cause decreased CM proliferation resulting in left ventricular (LV) hypoplasia [15]. In addition, LVs from HLHS patients have cardiac damage associated with CM proliferation defects compared to healthy subjects [16]. These studies suggest that intrinsically defective cardiac differentiation and impaired CM proliferation are likely contributing to HLHS-associated heart defects. Further strengthening this hypothesis, we found that HLHS-patient-derived hPSC-CMs exhibited reduced proliferation compared to the parents [17]. There is a need to identify the potentially causative genes, which contribute to those processes described above and to elucidate their role in CHD/HLHS pathogenesis.

To advance CHD gene discovery, we have developed a multi-model systems
platform enabling to both rigorously prioritize candidate genes from whole-genome
sequencing (WGS) based on rare, predicted-damaging variants and their mode of
inheritance, and to functionally characterize gene function in complementary and
genetically tractable model systems: human induced pluripotent stem cells (hPSC), the
fruit fly *Drosophila melanogaster* and zebrafish *Danio rerio*. The genetic basis of cardiac
development, originally uncovered in *Drosophila*, is fundamentally conserved across
species [18-21] and ~80% of human disease genes have fly orthologs [22]. In addition,
the non-redundant fly genome together with the simple structure and function of the fly
heart allow straightforward genotype-phenotype correlations. Zebrafish [23-25], which
has a two-chambered heart and can be easily manipulated using morpholino injections
and CRISPR technologies to affect heart development and function. In addition,
phenotypes can be directly observed in the developing larva for several days post
fertilization [26]. Finally, cardiomyocytes (CMs) differentiated from hPSCs (hPSC-CMs)
enable to identify and quantify cellular phenotypes associated with human diseases,
including HLHS [7, 27-29] and are amenable to large scale functional screens [30, 31],
thereby enabling to serve both as a discovery and validation platform. This integrated
approach allows to rapidly identify novel HLHS-associated gene candidates and to
characterize their ability to regulate developmental processes associated with disease
(e.g., hypoplasia) [17].

Defective CM proliferation is likely a hallmark of HLHS [15-17], thus to uncover
novel regulators of human CM proliferation with potential links to HLHS, we performed a
whole genome siRNA screen (18,055 genes) using an EdU assay in hPSC-CMs, and
identified ribosomal proteins (RPs) as the major class of genes controlling CM
proliferation. Whole genome sequencing (WGS) of 25 poor-outcome HLHS proband-
parent trios followed by unbiased variant filtering, revealed an enrichment for rare,
predicted-damaging variants in RP genes. Moreover, analysis of a high-value family
(75H) comprised of a HLHS proband, his phenotypically normal parents, and a fifth
degree relative born with left-sided CHD led to the identification of a predicted-
damaging variant in RP protein gene *RPS15A* that segregated with disease. Consistent
with a central role for RPs in the regulation of heart development, heart-specific knock-

down (KD) of HLHS-associated RPs in *Drosophila* caused severe phenotypes, including
near complete heart-loss and lethality. Similarly, in zebrafish, *rps15a* CRISPR mutants
and morphants had greatly reduced heart size and CM number, looping defects and
diminished contractility.

In this context, a multi-model system evaluation (hPSC-CMs, flies and zebrafish)
of RP function show their important role on heart growth and differentiation and CM
proliferation by modulating the p53, Myc and Hippo pathways. Moreover, we find
evidence that RPs may regulate heart development and CM proliferation in a cardiac-
specific manner by synergistically interacting with core cardiac transcription factors such
as T-box, Nkx and Gata factors.

In sum, here we show that RP genes are potent regulators of CM proliferation,
cardiac growth and differentiation, consistent with a potentially critical role in the
hypoplastic phenotype of HLHS. We suggest that RP genes are an emerging class of
novel genetic effectors in HLHS/CHD.

Results

Whole genome siRNA screen identifies ribosomal proteins as central regulators of cardiomyocyte proliferation

Based on previous and our recent data, impaired cardiomyocyte (CM) proliferation is emerging as an important mechanism in HLHS pathogenesis [15-17]. To comprehensively map the human genome for novel regulators of CM proliferation, we screened a whole genome library of 18,055 siRNAs for their ability to modulate hPSC-CM proliferation. The overall approach included the quantitative evaluation of both DNA synthesis (using EdU (5-ethynyl-20-deoxyuridine) incorporation rate, a thymidine nucleoside, which is incorporated into newly synthesized DNA) and total number of CMs post-treatment (Figure **1A-C**). For the primary screen (Figure **1A**), siRNAs were transfected into 25-day old hPSC-CMs [28, 32]. After 2 days, cells were co-stained for the CM sarcomere marker alpha-Actinin (ACTN2) and a thymidine nucleoside, EdU, which is incorporated into newly synthesized DNA and DAPI. The number of EdU/alpha-Actinin double-positive cells, and the total number of CMs were automatically quantified using the approach described in [30]. In total, we found 153 siRNAs that decreased proliferation (< 0.5-fold EdU incorporation) and number of CMs (<0.8-fold), and 162 siRNAs that increased EdU (>1.2-fold) and CM number (>1.1-fold; Figure **1B, C**). Consistent with previous studies [33, 34], KD of cell cycle checkpoint agonist, CHEK1 and MDM2, the negative regulator of TP53, both were among top hits that reduced CM proliferation. As expected, we found TP53 and CDKN1A among the genes that significantly increased CM cell number upon KD (Figure **1B, C**). To gain further insight into the molecular pathways regulating proliferation in hPSC-CMs, we performed Gene Ontology (GO) term analysis of hits decreasing EdU incorporation or CM numbers and found an enrichment for genes associated with "translation/ribosome" and p53 signaling as top hits (Figure **1D, E**). This is consistent with their role for proliferation (Figure **1C**) [for review 35]. We had previously found that the p53 pathway is dysregulated in hPSCs differentiated from a HLHS family trio [17]. Remarkably, the most represented gene family are ribosomal proteins (RPs), KD of which caused consistently the strongest inhibition of cell proliferation (Figure **1B**). These results were validated in human

ventricular-like iPSC-CMs (method see [36]) by systematic siRNA mediated KD of 80
RP genes. We found that KD of 59/80 of these ribosomal subunits significantly reduced
proliferation in CMs (p<0.05; Supplemental Figure **1A, B**), a finding consistent with our
hypothesis that RP expression is essential for CM proliferation and thus may contribute
to HLHS and other CHDs.

Enrichment of RP gene variants in an HLHS patient cohort with poor clinical
outcome

To determine if RPs could be involved in HLHS pathogenesis as modulators of
cardiac cell proliferation, we performed whole genome sequencing (WGS) and rare
variant filtering (RVF) (see also [17], and Methods: WGS and bioinformatic strategies) to
evaluate a cohort of 25 HLHS patient-parent trios with poor clinical outcome for rare
(MAF < 1%), predicted-damaging variants (CADD > 10) in RP genes. Poor clinical
outcome was defined as either prenatal – restrictive atrial septal defect (n=2); postnatal
– reduced right ventricular ejection fraction following stage II or III surgical palliation
(n=19); protein-losing enteropathy (n=2); or cardiac transplantation/failed surgical
palliation (n=2). Predisposition to CHD was excluded by echocardiography of the
parents in all but two families, in which a bicuspid aortic valve was present in the
mother. In this context, RVF yielded 292 unique HLHS candidate genes that primary fit
a recessive mode of inheritance (Figure **2A**). To determine whether certain gene
networks were over-represented among these variants, we used two online
bioinformatics tools (STRING and PANTHER [37, 38]). After applying Fisher's exact test
and false discovery rate corrections, RPs were the most enriched class of proteins
when compared to the reference proteome, which includes data annotated by protein
class (5.24-fold, p=0.0028), and cellular component (7.27-fold, p=0.011). In total, 14
variants found in 9 RP genes were identified, most fitting a recessive inheritance
disease model (Table **1**). These RP variants encompass mutations in upstream
promoter regions that potentially affect transcription factor binding sites, as well as non-
synonymous substitutions in the protein coding regions.

Next, all 292 prioritized candidate genes were systematically evaluated for
effects on the proliferation of hPSC-CMs *in vitro* and for cardiac differentiation of fly

hearts *in vivo*. Again, RP genes (*RPL39, RPL26L1, RPS15, RPS17, RSPS28*) most
severely reduced proliferation of hPSC-CMs upon KD (Figure **2B**), consistent with our
genome-wide proliferation screen (see Figure **1B**). In the fly, heart-specific KD of RPs
throughout development led to partial or complete heart loss (*RpL26, RpL36A, RpL3*) by
the end of metamorphosis or even lethality (*RpS17, RpL39, RpS15, RpL26, RpL36A*)
(Supplemental Figure **2A**), again consistent with a critical role in cardiogenesis. Further,
KD of *RpL10* gave rise to severely constricted hearts, while KD of *RpS28b* caused
inflow tract defects (Supplemental Figure **2A**). We also validated a subset of the RP
candidate genes in our zebrafish model and found that KD of *rpl39* leads to reduced
ventricle size, whereas *rps17* CRISPR mutants exhibit systolic dysfunction
(Supplemental Figure **2B, C**). In sum, our analysis of all candidate genes by STRING,
PANTHER, and gene KD in hPSC-CM, fly and/or zebrafish model systems show a
functional enrichment for RP genes, potentially linking defective cardiogenesis and
HLHS.
209

HLHS-patient derived RPS15A variant segregates with disease

In addition to the 25 families selected based upon poor clinical outcome, a rare
familial HLHS case (75H) was included for analysis. This family was comprised of the
proband with HLHS, his phenotypically normal parents, and a 5th degree relative born
with left-sided CHD (bicuspid aortic valve and coarctation of the aorta) (Figure **2C**). At
age 13, the 75H proband was in the 22nd percentile for weight and 10th percentile for
height, indicative of an overall growth defect. We postulated a heterozygous driver
mutation with incomplete penetrance and variable expression. WGS data filtered for
rare, predicted-damaging variants in coding and regulatory regions revealed six top
rare, predicted-damaging variants (*WDR33, NADK2, RSL1D1, RPS15A, GDE1,*
ACSF2; Supplemental Table **3**) that were shared by the HLHS proband, the unaffected
mother and the 5th degree relative of the proband with CHD (Figure **2C**). Interestingly,
we had previously reported diminished total cell numbers and EdU incorporation in 75H
proband-derived hPSC compared with those of the parents [17].
To explore whether the top six candidate genes (*WDR33, NADK2, RSL1D1,*
RPS15A, GDE1, ACSF2) may play a role in proliferation, we functionally evaluated their

role by KD in hPSC-CMs proliferation *in vitro* and on cardiac differentiation in fly hearts
in vivo. Although KD of some of the other 5 prioritized genes of the 75H family also
reduced CM proliferation, *RPS15A* KD induced by far the most severe phenotype
(>85% reduction in proliferation) and thus *RPS15A* emerged as the top candidate
(Figure **2D, E**). In this context, the *RPS15A* variant was harbored in a TF binding site-
rich domain and was inherited from the mother (Supplemental Figure **3A, B**). For further
validation, we also used siRNA to KD *RPS15A* in hPSCs derived from the father, who
does not carry the *RPS15A* variant. KD in these cells caused a reduction in hPSCs
numbers, compared to non-transfected cells, indicating reduced cell proliferation
(Supplemental Figure **3C-E**), which is consistent with the effect of siRNA-mediated
RPS15A KD in generic hPSC-CMs (Figure **2D**). Taken together these results indicate
that mechanisms decreasing *RPS15A* expression contribute to impaired cardiomyocyte
proliferation and likely affect associated heart developmental processes.
239
RPS15A KD in *Drosophila* and zebrafish causes severe cardiac proliferation and
differentiation defects

To characterize the role of *RPS15A* during heart development, we first induced a
heart-specific KD of *RpS15Aa* in flies using *Hand*[4.2]-Gal4 driver [39], which caused a
partial or complete loss of the heart (Figure **2F,G**). Note that this phenotype is
consistent with the results from our previous study involving another RP gene (*RPL13*)
[40].
To further evaluate the role of *RP* genes during heart development, we knocked-
out *rps15a* in zebrafish (*Danio rerio*) using CRISPR [23-25]. We examined F_0 larva at 72
hpf (hours post fertilization) using high speed digital imaging (SOHA [41], see also
methods) and confocal microscopy to monitor heart size and cardiomyocyte numbers
respectively. Remarkably, *rps15a* mutants hearts were smaller in size (Supplemental
Fig. **2D,E**), with reduced CM numbers (Figure **2H,I**). Interestingly, CM numbers were
predominantly reduced in the ventricle compared to the atrium (Figure **2H)**. We
observed similar effects in response to injection of a *rps15a* morpholino (MO) compared
to uninjected larva [42, 43] (Supplemental Figure **4**). In this context, we also noted that
the overall body plan and morphology of *rps15a* CRISPR mutants or morphants were

largely unaffected, except for a mild pericardial edema, an indicator of heart dysfunction

(**Figure 2I**) [44], and thus suggesting an exacerbated requirement of *rps15a* function for

cardiac tissues as compared to others during early embryonic development.

Collectively, these data support the hypothesis that *RPS15A* is required for CM

proliferation and heart morphogenesis (hPSC-CMs, fly and zebrafish), thus suggesting

a potential role for RPs as genetic drivers of hypoplasticity observed in HLHS or defects

in other CHDs.

Ribosomal proteins control CM cell cycle by regulating TP53 pathway activity

To investigate how RPs regulate cell cycle activity in CMs, we performed RNA-

seq upon KD of *RPS15A* and *RPL39*, which belong to the small and the large ribosomal

subunits that harbor predicted-damaging variants in 75H and 151H probands,

respectively. Comparison of differential gene expression between *siRPS15A* and

siRPL39 KD revealed that ~53% of genes were commonly dysregulated (Figure **3A**),

indicating the existence of a conserved RP-dependent transcriptional network.

Consistent with a central role for RPs in the regulation of proliferation, GO term analysis

for differentially expressed genes revealed an enrichment for genes involved in DNA

replication, mitosis and DNA damage response mediated by p53, and included the

downregulation of positive regulators of cell cycle such as *CDK1, CCNA2, AURKA,*

PCNA and the upregulation of cell cycle arrest mediators such as *CDKN1A, BTG2,*

GADD45A (**Figure 3B and Supplemental Tables 5&7**). To confirm these findings, we

performed immunostaining for canonical p53 downstream transcriptional target [45],

CDKN1A, and observed that the percentage of CDKN1A+ CMs was increased by ~60%

in response to *RPS15A* KD (**Figure 3C, D**), indicating that RP KD induces cell cycle

arrest *via* the activation of the p53 signaling pathway in hPSC-CMs.

Next, to evaluate if the reduction in proliferation caused by RP KD is mediated by

the p53 signaling pathway in CMs, we co-KD *TP53* or *CDKN1A* along with *RPS15A*,

and observed a significant rescue of CM proliferation by EdU incorporation and CM

number in comparison to RPS15A KD (**Figure 3E, F and Supplemental Figure 5A, B**).

Next, we tested if RP-mediated defects in zebrafish can also be rescued by

inhibition of p53. To this aim, we used morpholinos to co-KD *p53* with *rps15a* [46] and

examined larval hearts at 72 hpf. *p53* MO-mediated KD on its own had little effect on
heart function but partially reversed the *rps15a* MO-mediated reduction in heart size and
cardiomyocyte numbers (Figure **3G, H**). Moreover, bradycardia, heart looping and
reduced contractility phenotypes of *rps15a* morphants were also rescued by co-KD of
p53 (**Supplemental Figure 5C, D)**. These observations robustly support our hypothesis
that RP-dependent control of proliferation is a critical mechanism in cardiac
development, since we observe upon by *p53* KD restoration towards normal CM
proliferation rates and numbers, as well as heart size und function is zebrafish.
Collectively, our data demonstrate that RPs regulate CM proliferation by modulating the
activity of the p53 pathway.

Heart loss in *Drosophila* by RpS15Aa KD is Myc-dependent and is partially rescued by Hippo pathway activation

The fly heart develops similarly to the vertebrate heart at early stages [19] and a
link between RPs and cell cycle-regulating pathways, such as p53 and Hippo pathways
[47], has been proposed to be conserved between mammals and flies [48]. To test
whether p53 has a function in fly heart development similar to hPSC-CMs and
zebrafish, we performed cardiac co-KD of *RpS15Aa* and *p53* and examined heart
structure and function in flies *in vivo*. However, co-KD did not rescue the cardiac defects
of *RpS15Aa* KD suggesting that *p53* has likely different context-dependent roles in flies,
as compared to vertebrates, as has been reported previously [49].

Vertebrate TP53 acts through negative regulation of the Hippo pathway in growth
and proliferation [50]. Indeed, YAP, a downstream effector of Hippo, promotes CM
proliferation in the mouse heart [51]. We therefore tested if YAP/yorkie can substitute
the function of p53 in the fly heart and found that overexpressing the Hippo pathway
gene *yorkie* (*yki*), the fly ortholog of YAP, in the developing heart considerably restored
RpS15Aa KD-induced heart loss in *Drosophila* (Figure **4A',B**). We also observe
formation of adult ostial structures, which indicates that the larval heart underwent
partial remodeling to an adult heart during metamorphosis. Further, we found that *yki*-
mediated rescue depends on the transcriptional co-factor encoded by *scalloped* (*sd*,

Drosophila TEAD1/2/3/4), since upon *sd* KD, *yki* OE can no longer rescue the *RpS15Aa*
KD-induced heart loss (Figure **4A", B**). Moreover, KD of *sd* in an *RpS15Aa* KD
background (without *yki* OE) worsens the *RpS15Aa* KD phenotype (Figure **4A", B**).

Next, we tested the oncogenic transcription factor *Myc*, which is a well-known
master regulator of ribosome biogenesis and regulates the expression of several
components of the protein synthesis machinery, including RP gene expression [52]. co-
KD of *Myc* and *RpS15Aa* restored heart structures predominantly in the anterior
segments of the abdomen (A1-A3), while *Myc* KD by itself had little effect (Figure **4A'",**
C). The restored hearts exhibit adult-like heart structures and features; however,
myofibrils were poorly developed, possibly due to a lack of sufficient protein synthesis.
328

RPS15A **genetically** **interacts** **with** **cardiac** **transcription** **factors**
TBX5/*tbx5a/Dorsocross***, *nkx2.7*/*tinman,** **and** ***Gata4,5,6/pannier*** **in model systems**

The profound importance of RPs for cell growth and proliferation of most cell
types ([53] and **Supplemental Fig 1C, D**), raises the question of how tissue specific
phenotypes such as those observed in HLHS can arise from the defective function of
ubiquitously expressed genes. To address this apparent paradox, we hypothesized that
RPs might functionally interact with tissue-specific proteins such as cardiac transcription
factors (cTFs), to control CM proliferation. Analysis of the impact of cTFs on hPSC-CM
proliferation from our whole genome screen, revealed that KD of most cTFs did not
cause major proliferation defects (except for e.g., *HES4* and *HOPX*; Figure **5A**). Among
the cTFs, TBX5 is specifically expressed in the left ventricle at stages of intense CM
proliferation [54] and thus we next asked if *TBX5* could functionally interact with RPs.
Remarkably, while hPSC-CM proliferation was not affected by increasing doses of
siTBX5 (0.5-2nM), increasing si*TBX5* dosage in siRP backgrounds led to proportional
decrease in EdU incorporation (Two-way ANOVA; Figure **5B**), thereby indicating that
RPs and *TBX5* genetically interact to regulate proliferation in hPSC-CMs.

Conservation of genetic interactions between human and fly cardiac transcription
factors and constitutive genes have been identified before [55]. We therefore specifically
tested for genetic interaction between *RpS15Aa* and the cardiac TFs *tinman/NKX2-5,*

pannier/GATA4,5,6 and *Dorsocross/TBX5* in adult *Drosophila* hearts. A heterozygous

deficiency covering *RpS15Aa* causes moderate dilation of hearts compared to controls

(Supplemental Figure **6C)**. However, when *RpS15Aa* was placed *in trans* to loss of

function alleles of cardiac TFs *tinman, pannier* or *Dorsocross1/2/3*, these hearts

exhibited significantly deformed hearts, which is only rarely observed in the single

heterozygotes (Figure **6C, D**). In addition, *RpS15Aa* heterozygous flies showed a

prolonged heart period when combined with a *tinman* or *pannier* heterozygous

mutations (**Supplemental Figure 6C**).

Next, we tested whether we can also detect genetic interactions between *rps15a*

and the cardiac TFs *nkx2.7* or *tbx5a* in zebrafish. Zebrafish expresses the NKX2-5

ortholog *nkx2.7* in the heart and functional studies have shown that both *nkx2.5* and

nkx2.7 play critical roles in cardiac development [56]. To determine whether *rps15a* and

nkx2.7 or tbx5a genetically interact in zebrafish, we injected low doses of *rps15a* [42]

MO, in combination with *nkx2.7* [57] or *tbx5a* MO. *nkx2.7* MO alone had little effect on

heart size, cross-sectional area, or contractility, whereas double morphants exhibited

cardiac dysfunction, with contraction virtually abolished in some animals (**Supplemental**

Figure 6D). Furthermore, we see a significant prolongation of the heart period in double

morphants (*rps15a + nkx2.7* or *rps15a + tbx5a*) in comparison to each MO alone (Two-

way ANOVA; **Supplemental Figure 6D, E**) consistent with the effects observed in

Drosophila. Together, these results highlight the existence of evolutionarily conserved

genetic interactions between RPs and core cardiogenic genes in heart development.

RP-regulated HLHS-associated genes control proliferation in a CM-specific

manner

Previous studies and this work show that reduced RP function can lead to tissue-

specific developmental defects, that in turn can be rescued by loss of p53 [58, 59].

While these findings highlight a downstream role for p53 in the development of RP-

dependent phenotypes, they also imply that RPs can regulate cell cycle and/or p53

activity in a tissue-specific manner. Thus, to delineate how RPs might control

proliferation in a CM-specific manner, we compared differential gene expression profiles

upon the two RP KDs in hPSC-CMs and undifferentiated hPSCs (**Figure 6A**).
Consistent with our hypothesis, this analysis revealed that RPs regulate the expression
of 493 genes in a CM-specific manner (**Supplemental Tables 5-8**), thereby suggesting
the existence of a cell type-specific (cardiac) transcriptional response to RP loss of
function.

Next, to evaluate whether HLHS-associated genes were part of this lineage-
specific transcriptional response, we selected those differentially expressed genes
harboring rare and predicted damaging variants in probands from the poor outcome
cohort and 75H family (**Supplemental Tables 2, 3)**. Remarkably, this prioritization
strategy identified 12 genes potentially associated with HLHS (**Supplemental Table 9**),
6 of which were found to also regulate cell cycle activity in hPSC-CMs (**Figure 6B, C**).
Thus, collectively this approach led us to identify an RP-dependent and cardiac-specific
HLHS-associated gene network that supports CM proliferation *via* the upregulation of
EWSR1, MDC1, PKMYT1 and *KIF1C,* and downregulation of *FAT4* and *EPHA4* (**Figure**
6D, E).

To further explore if RP-regulated HLHS-associated genes control proliferation in
a cell type-specific manner, we asked if *EWSR1* KD*,* which elicited the strongest
proliferation phenotype in hPSC-CMs, could regulate proliferation in non-cardiac cell
types such hPSCs. In contrast to hPSC-CMs, siEWSR1 did not affect the number of
OCT4+ cells (**Figure 6F, G**), which suggests that EWSR1 is able to regulate
proliferation CM-specifically. EWSR1 is an RNA/DNA binding protein that regulates
transcription and RNA splicing and plays a major role as oncogenic driver when fused to
ETS transcription factors [60]. In a next step, we tested if EWSR1 regulates CM
proliferation by modulating the p53 pathway. Consistent with this hypothesis,
immunostaining for p53 downstream target, CDKN1A, revealed that EWSR1 KD both
increased the percentage of CDKN1A-positive CMs and decreased EdU incorporation
as compared to siControl (**Figure 6H-J**). Of note, in flies *RpS15Aa* genetically interacts
with *cabeza* (*caz*), the ortholog of *EWSR1* as can be seen by prolongation of systolic
interval lengths (**Supplemental Figure 6F)**. Collectively, these results support the
conclusion that RPs can modulate cell cycle activity in cell type specific manner, by

controlling the expression of downstream effectors, such as EWSR1, with a CM-specific

ability to modulate the p53 pathway activity (**Figure 6K, Figure 7**).

Discussion

Implication of ribosomal proteins as genetic modulators in HLHS/CHD pathogenesis

Recent work, including our own, strongly suggest that defective cardiac differentiation and impaired CM proliferation contribute to HLHS-associated heart defects [15-17]. In this study, we find that ribosomal proteins are critical for maintaining CM proliferation, as well as cardiac structure and function in fish and fly heart models. We show a potential role for RP function in cardiac development and HLHS/CHD pathogenesis: (1) RPs are central regulators of cardiomyocyte proliferation; (2) RP variants are enriched in a cohort of poor-outcome HLHS patients; (3) a rare predicted-damaging promoter variant in *RPS15A* was found to segregate with CHD within an HLHS family (75H); (4) KD of RPs *in vivo* results in cardiac deficiencies in hPSC-CMs, *Drosophila* and zebrafish, and (5) induces TP53 signaling and blocks proliferation that can be alleviated by inhibition of TP53 in the vertebrate models. Interestingly, the transcriptomic response of another HLHS patient-proband trio 5H [17] paralleled these findings and raises the possibility of an underlying ribosomopathy condition in that HLHS family. While universally important for cellular growth, an increasing number of variants in RP genes have been linked to CHD in humans indicating tissue-specific differences in the penetrance of RP gene mutations. Most notably, ~30% of patients with Diamond-Blackfan anemia, a ribosomopathy characterized by hypo-proliferative, proapoptotic erythropoiesis, also have CHD [61]. Moreover, *RpL13* was recently identified as a potential candidate gene involved in CHD from a screen for *de novo* copy number variations (CNVs) in 167 patients with CHD [40]. Furthermore, the Pediatric Cardiac Genomics Consortium (PCGC) exome dataset of 2871 patients with CHD identified several rare, predicted-damaging *de novo* variants in RP genes, 2 of which were found in patients with HLHS [62]. Our finding that RPs genetically interact with core cardiac transcription factors provides a potential mechanism for the cardiac specificity of RP phenotypes. We hypothesize that RP gene variants might play a role as genetic modifiers (or sensitizers) in the oligogenic pathogenesis of HLHS.

An RP–MDM2–p53 surveillance network in heart development

Defects in ribosome biogenesis caused, for example, by reduction in RP gene
copy numbers induce a stress response program that activates TP53 (p53) and a
cascade of cellular events resulting in apoptosis, inhibition of the cell cycle or DNA
damage response (reviewed in e.g. [63]), commonly referred to as nucleolar stress
response [64] with activation of TP53 being a key hallmark [65]. A key mechanism
involves the release of RPs to the nucleoplasm, where several RPs bind and inhibit
MDM2, which again results in p53 stabilization and pathway activation [66, 67]. A recent
study showed that RP haploinsufficiency in the developing mouse limb bud also
activates a common TP53 cascade but results in TP53-dependent tissue-specific
changes of the translatome, which might confer the specificity often observed in
ribosomopathy [58]. The TP53-MDM2 feedback loop is the central molecular node in
response to a wide variety of stress signals, including in the human diseased adult heart
[68, 69]. As mentioned above, the transcriptomic response of the HLHS family 5H [17]
also showed activation of the TP53 pathway potentially due to an underlying
ribosomopathy. Since low RP levels induce a proliferation blockade that can be
overridden by p53-p21/CDKN1A KD, we hypothesize that RP levels may act as
signaling components sensing cellular fitness and with a functional outcome either
being P53 activation or non-activation. Such an RP–MDM2–p53 surveillance network
was previously proposed to be important in response to nutrient availability changes
and inhibition of oncogenic activity [70, 71]. The inhibition of the RP-MDM2-P53 axis
might be a therapeutic avenue to consider for functional intervention. So far, modulation
of the MDM2-P53 network, including the development of *p53* re-activation drugs, MDM2
repressors or inhibitors of the MDM2-P53 interaction, has been a focus in cancer
therapy [72, 73]. However, in this study cardiac defects can be ameliorated by *p53*
inhibition and not by *p53* activation, which holds major risks like cancer development.
Further studies are needed, to identify the upstream mechanisms leading to the *p53*
pathway activation we observed in the HLHS proband cells.

Heart remodeling and differentiation is dependent on Hippo pathway and Myc in *Drosophila*

Heart-specific KD of *RpS15Aa* causes constriction of larval hearts and atrophy in adult hearts, as well as severe heart loss during metamorphosis, none of which could be rescued by p53 reduction, unlike in hPSC-CMs and zebrafish. We hypothesize that this might be due to different, context-dependent roles of *p53* in flies, as it was previously reported that loss of RPs can induce nucleolar stress and *Minute*-like phenotypes [74]. However, in contrast to humans, apoptosis caused by nucleolar stress in *Drosophila* was found to be induced by JNK-dependent mechanisms [75], independently of *p53*. We hypothesize that the loss of RPs in flies, in conjunction with reduced protein synthesis, might cause nucleolar stress, triggering a cell-intrinsic signaling cascade that prevents the heart to further differentiate and grow.

We also found that co-knockdown of *Myc* can partially rescue the defects found in the anterior segments of the heart caused by cardiac *RpS15Aa* KD. There has been recent findings that the role of MYC as the master regulator of ribosome biogenesis is conserved between humans and flies [76]. In human cell lines, MYC was shown to control the impaired ribosome biogenesis checkpoint (IRBC) complex, RPL5, RPL11, and 5SrRNA, which binds and inhibits MDM2, thereby stabilizing TP53. MYC depletion decreases the availability of the IRBC complex [77]. As a feedback mechanism, RPL5 and RPL11 have been reported to be negative regulators of MYC expression during ribosomal biogenesis [78]. Consistently, in response to nucleolar stress, when ribosome-free RPs are released from the nucleolus, MYC was found to be downregulated [65]. We hypothesize that reduction of *Myc* in flies might ameliorate nucleolar stress as well as reduce downstream stress responses resulting in partial rescue of heart defects.

The role of the Hippo pathway to regulate cell growth/organ size, proliferation, and survival, and its importance in cardiac biology is conserved between humans and fly [79-82]. The Hippo-YAP pathway is a cell-intrinsic pathway that regulates cardiomyocyte proliferation and thus heart size during development. For example, activated YAP was able to drive postnatal cardiomyocytes to re-enter the cell cycle;

making Hippo signaling a promising therapeutic target for cardiac regenerative medicine
[83]. Here, we provide evidence that overexpression the *Drosophila* ortholog of
YAP/TAZ, Yorkie, partially rescues the *RpS15Aa* phenotype (Figure **4**). In *Drosophila*
flight muscles it was found that the Hippo pathway and Yorkie, downstream of Dlg5 and
STRIPAK, can control timing and levels of sarcomeric genes, thus promoting muscle
morphogenesis [84]. Further evidence suggests that YAP1 is not only an important
regulator of cardiomyocyte proliferation in the embryo, but also promotes cardiomyocyte
survival and growth in the postnatal heart, which is in line with findings in *Drosophila*
flight muscles, which also increase their size via post-mitotic muscle growth [85, 86].

The rescue of the *RpS15Aa* phenotype by Yorkie was dependent on its
downstream factor *scalloped* (the *Drosophila* ortholog of *TEAD1/2/3/4*), since
overexpression of *yorkie* could no longer rescue the *RpS15Aa* phenotype with *scalloped*
KD, confirming the epistatic relationship between YAP and TEAD co-factors.
Interestingly, a proband among the PCGC HLHS patients was transheterozygous for
mutations in *RPL15* and *TEAD4* [62], making this an interesting disease candidate pair.

The incomplete rescue by *yorkie* overexpression and *Myc* KD highlights the
complexity of the RP loss phenotype and points towards involvement of further critical
genetic components contributing to gene network disturbance mediated by RP loss and
needs further investigation.

Overall, our results point towards a critical role of ribosomal protein for heart
development and function in *Drosophila* with growth and differentiation as essential
factors depended on ribosome biogenesis master regulator *Myc* and Hippo pathway
effector gene *yorkie*. Further investigations are needed to identify other genes and
pathways involved in cardiac phenotype manifestation based in RP loss.

Cardiac-specific and RP-dependent regulation of proliferation in the context of
HLHS

Defective proliferation in left ventricular CMs is a phenotypic hallmark of HLHS
[15, 16], thereby implying the existence of HLHS-associated mechanisms regulating

proliferation in a CM-specific specific-manner. In this study, we identified RPs as novel
candidate genetic drivers of hypoplastic phenotypes observed in HLHS, as 1) rare,
predicted damaging variants affecting RP genes are enriched in HLHS probands as
compared to healthy controls, 2) KD of most RPs impairs proliferation in hiPSC-CMs
(59/80 tested) and heart development in flies (6/6 tested), and 3) systemic loss of
rps15A function causes heart-specific hypoplastic phenotypes in zebrafish. However, in
this context, the evaluation of RPs function in multiple cell types revealed that they are
generally required for proliferation (hPSCs, hPSC-CMs and neonatal dermal
fibroblasts), thus indicating that RP loss of function triggers a non-cell type specific cell
cycle block. Collectively, these observations imply that cell type-specific regulators of
RP expression might enable to regulate proliferation in both a RP-dependent and
tissue-specific manner. Consistent with this model, all probands harboring rare,
predicted-damaging variants in RPs contain mutations affecting their promoter regions
(**Table 1**). Remarkably, several of these mutations are predicted to disrupt the binding
site for HLHS-associated TF, ETS1 [14, 87], and their KD is also found to impair
proliferation in our whole genome screen (0.67 EdU; **Supplemental Table 1**). Thus, we
speculate that spatially restricted TFs controlling RPs expression represent a promising
gene class to modulate proliferation in a tissue-specific manner. In addition, tissue
restricted modifiers of RPs activity represent an appealing alternative strategy to
mediate RP-dependent proliferation. Consistent with this hypothesis, cardiac TFs, such
as Tbx20, have been found to physically interact with RPs [88]. Consistent with this
mechanism, our data show that *TBX5* loss function can exacerbate the effect of a
hypomorphic RP loss of function on proliferation in hPSC-CMs and heart development
in flies, thereby indicating the likely existence of genetic interactions between RPs and
core cardiogenic genes during heart development. In this context, *Tbx5* that has an
expression pattern restricted to the left ventricle at a stage of intense CM proliferation
[54, 89] represents a promising modifier candidate of RP activity to drive hypoplasia in
the left ventricle. Interestingly, hPSC-CMs homozygous mutant for *TBX5* show
downregulation of most RP genes, independent of genetic background of the cell line
[90]. While *Tbx5* mouse models do not have a hypoplastic left ventricle, and we did not
find *TBX5* variants in our HLHS cohort, these observations strengthen the idea that

during development of the left ventricle a genetic program ensures robust expression of
RP genes needed for CM proliferation and ventricular growth.

Finally, a third mechanism by which RPs might control proliferation in a CM-
specific manner, is based on the hypothesis that CMs may be intrinsically sensitive to
RP loss of function. Consistently , our comparative transcriptomics analysis (**Fig. 3**)
revealed that RPs may be involved in regulating transcription in a CM-specific manner.
Among these CM-specific regulated genes, *EWSR1, MDC1, PKMYT1, KIF1C, FAT4*
and EPHA4, were found to be associated with HLHS and to regulate CM proliferation
(**Figure 6**). Remarkably, EWSR1 KD did not affect proliferation in hPSCs while it
strongly reduced EdU incorporation in hPSC-CMs, thus suggesting that EWSR1
regulates proliferation in a CM-specific manner. Interestingly, in flies *RpS15Aa*
genetically interacts with *cabeza* (*caz*, the fly *EWSR1*). Consistent with our
observations, a recent study has shown that overexpression of a fusion Ewsr1-Fli1
protein in mice specifically induces dilated cardiomyopathy by promoting apoptosis in
cardiac myocytes [91]. Similarly, Fat4, a negative regulator of the hippo pathway, which
is upregulated upon RP KD was found to specifically regulate heart size via regulation
of cardiomyocyte of size and proliferation [92]. Thus, collectively we propose that RPs
represent a central regulatory hub for cell proliferation during embryonic development
which can be modulated in a cell type-specific manner by tissue-restricted modulators of
RP expression and/or activity.

Acknowledgements

This work was supported by a grant from the Wanek Foundation at Mayo Clinic
in Rochester, M.N., to J.L.T., T.J.N., T.M.O., R.B. and A.R.C. We gratefully
acknowledge the patients and families who participated in this study. We thank Marco
Tamayo for excellent technical assistance. This work was supported by National
Institutes of Health (R01 HL054732 to R.B.; R01 HL153645, R01 HL148827, R01
HL149992, R01 AG071464 to A.R.C.); by California Institute for Regenerative Medicine
(DISC2-10110 to A.R.C.); by the American Heart Association (AHA Predoctoral
Fellowship 18PRE33960593 to K.B.).

MATERIALS AND METHODS

Key resources table

Reagent type (species) or resource	Designation	Source or reference	Identifiers	Additional information
Genetic reagent (*D. melanogaster*)	*Hand*$^{4.2}$-Gal4	NA	PMID: 16467358	NA
Genetic reagent (*D. melanogaster*)	R94C02::tdTomato	Y. N. Jan lab	FBtp0137272	NA
Genetic reagent (*D. melanogaster*)	UAS-RpS15Aa^{RNAi}	Vienna Drosophila Resource Center (VDRC)	FBgn0010198	v19198
Genetic reagent (*D. melanogaster*)	Df(RpS15Aa)	Bloomington Drosophila Stock Center (BDSC)	FBab0047266	39614
Genetic reagent (*D. melanogaster*)	UAS-RpL26^{RNAi}	Vienna Drosophila Resource Center (VDRC)	FBgn0036825	v40402 v100280
Genetic reagent (*D. melanogaster*)	UAS-RpL36A^{RNAi}	Vienna Drosophila Resource Center (VDRC)	FBgn0031980	v108391
Genetic reagent (*D. melanogaster*)	UAS-RpS15^{RNAi}	Vienna Drosophila Resource Center (VDRC)	FBgn0034138	v35415 v104439
Genetic reagent (*D. melanogaster*)	UAS-RpL39^{RNAi}	Vienna Drosophila Resource Center (VDRC)	FBgn0023170	v23578 v108821
Genetic reagent (*D. melanogaster*)	UAS-RpL3^{RNAi}	Vienna Drosophila Resource Center (VDRC)	FBgn0020910	v109820
Genetic reagent (*D. melanogaster*)	UAS-yorkie	D. Pan	NA	NA
Genetic reagent (*D. melanogaster*)	UAS-Myc^{RNAi}	Bloomington Drosophila Stock Center (BDSC)	FBgn0262656	25784
Genetic reagent (*D. melanogaster*)	UAS-sd^{RNAi}	Vienna Drosophila Resource Center (VDRC)	FBgn0003345	v101497
Genetic reagent (*D. melanogaster*)	*Df(3L)DocA*	I. Reim	Fbab0037663	NA
Genetic reagent (*D. melanogaster*)	tin^{EC40}	Bloomington Drosophila Stock Center (BDSC)	Fbal0032861	78560
Genetic reagent (*D. melanogaster*)	tin^{346}	Bloomington Drosophila Stock	Fbal0035787	92964

		Center (BDSC)		
Genetic reagent (*D. melanogaster*)	pnr[VX6]	Bloomington Drosophila Stock Center (BDSC)	Fbal0032468	6334
Genetic reagent (*D. melanogaster*)	Df(pnr)	Bloomington Drosophila Stock Center (BDSC)	Fbab0038315	7982
strain, strain background (*Danio rerio*)	Oregon AB wild-type			A commonly used wildtype strain
strain, strain background (*Danio rerio*)	*Tg(myl7:EGFP)[twu277]*	Tsai Lab, National Taiwan University	PMID:12950077	A transgenic line of zebrafish labeled with heart-specific EGFP fluorescence.
Strain, strain background (*Danio rerio*)	*Tg(myl7:H2A-mCherry)[sd12]*	Yelon Lab, University of California, San Diego	PMID:24075907	A transgenic line of zebrafish specifically expressing mCherry in cardiomyocyte nuclei.
Antibody	mouse monoclonal anti-ACTN1	Sigma	A7811	1:800
Antibody	Mouse monoclonal anti-POU5F1 (OCT4)	Sigma	P0082	1:500
Antibody	donkey polyclonal anti-mouse Alexa Fluor 568	Invitrogen	A10037	1:500
Antibody	chicken polyclonal anti-GFP	Aves Labs	GFP-1020	1:300
Antibody	rabbit polyclonal anti-mCherry	Rockland	600-401-P16S	1:200
Antibody	donkey polyclonal anti-chicken AlexaFluor 488	Jackson ImmunoResearch	703-545-155	1:200
Antibody	donkey polyclonal anti-rabbit AlexaFluor 568	Invitrogen	A10042	1:200
other	DAPI (iPSC) 500mg/mL	Sigma	D9542	1:1000
Antibody	mouse anti-Mhc (*Drosophila*)	DSHB	3E8-3D3	1:50
Antibody	anti-mouse-Alexa Fluor 488	Jackson Labs	115-545-003	1:500
other	Alexa Fluor 647 phalloidin	Invitrogen	A22287	1:500
other	DAPI (Zebrafish) 500 mg/mL	Invitrogen	D1306	1:200
Sequence based	RPS15A siRNA	Entrez Gene ID: 6210	Dharmacon	On-Target plus,

reagent				individual sequence
sequence-based reagent	TP53 siRNA	Entrez Gene ID: 7157	Dharmacon	On-Target plus, Individual Sequence
sequence-based reagent	CDKN1A siRNA	Entrez Gene ID: 1026	Dharmacon	On-Target plus, SmartPool
sequence-based reagent	TP53	371502118c1	IDT Integrated DNA technologies, Coralville, IA	Expression level
sequence-based reagent	CDKN1A	310832423c1	IDT Integrated DNA technologies, Coralville, IA	Expression level
sequence-based reagent	CCNB1	356582356c1	IDT Integrated DNA technologies, Coralville, IA	Expression level
sequence-based reagent	CCNB2	332205979c1	IDT Integrated DNA technologies, Coralville, IA	Expression level
sequence-based reagent	CDK1	281427275c1	IDT Integrated DNA technologies, Coralville, IA	Expression level
sequence-based reagent	MCM2	33356546c1	IDT Integrated DNA technologies, Coralville, IA	Expression level
sequence-based reagent	RPS15A	71772358c2	IDT Integrated DNA technologies, Coralville, IA	Expression level
sequence-based reagent	GAPDH	Hs.PT.45.8326	IDT Integrated DNA technologies, Coralville, IA	Expression level
commercial assay or kit	EdU	Click-it Plus EdU Imaging Kit	Life Technologies	
software, algorithm	Prism v7 and v8		GraphPad Software	

Study subjects

Written informed consent was obtained for the index family and an HLHS cohort, under a research protocol approved by the Mayo Clinic Institutional Review Board. Cardiac anatomy was assessed by echocardiography. Candidate genes were identified and prioritized by WGS of genomic DNA and RNA sequencing of patient-specific iPSC and cardiomyocytes. For variant burden analysis, controls were obtained from the Mayo Clinic Center for Individualized Medicine's Biobank. Methods for genomic analyses,

RNA Sequencing, iPSC technology, bioinformatics and statistics are described in the
Online Appendix. Data are available at NCBI GEO database.

WGS and bioinformatic strategies

Our methods for family phenotyping, WGS, variant filtering, and candidate gene
prioritization in the rare HLHS-CHD family and 25 HLHS proband-parent trios have
been previously described [7, 9, 17]. In brief, WGS of DNA isolated from blood or cheek
swabs was performed on a HiSeq 4000 platform at the Mayo Clinic Medical Genome
Facility. BAM files underwent primary and secondary analyses using an established
workflow with standard data quality metrics, and reads were aligned to the human hg38
reference genome. Variant call format files with single nucleotide variants and small
insertion-deletion (indel) calls were analyzed using Ingenuity Variant Analysis software
and knowledge database (Qiagen). To retain only high-confidence data, variants were
required to have a base call quality of at least 20 and to pass Variant Quality Score
Recalibration. Functionally annotated coding and regulatory variants underwent primary
filtering and prioritization by an iterative approach with variants required to have a minor
allele frequency (MAF) <0.01 across all races in gnomAD v2.1.[93] Variants predicted to
impact protein structure were retained and included missense, frameshift, stop-gain,
stop-loss, canonical splice and non-canonical variants predicted to disrupt splicing
based upon MaxEntScan[94]. Regulatory variants were defined as those that (a) impact
a microRNA or microRNA binding site (b) reside in an enhancer binding site annotated
in the VISTA database (http://enhancer.lbl.gov/) or (c) disrupt a predicted promoter or
transcription factor binding site informed by the position-weighted matrices available in
JASPAR (http://jaspar.cgb.ki.se/). Genes harboring a rare functional variant were further
required to have upper quartile cardiac expression during mouse embryonic (e14.5)
(Homsy et al., 2015) or human fetal heart development (ranked percentiles from
RNASeq experiments available in ENCODE: ENCSR047LLJ (120 day male);
ENCSR863BUL (91 day female); ENCSR000AEZ (28 week female and 19 week
female) (Davis et al., 2018).
For the HLHS-CHD family, a secondary segregation filter was applied to model
autosomal dominant inheritance with incomplete penetrance, which required sharing of

prioritized rare variants among affected family members. For the poor-outcome HLHS
proband-parent trios, a secondary Mendelian filter was applied to identify major-effect
driver variants that arose *de novo* or fit recessive modes of inheritance (i.e.,
homozygosity, hemizygosity, compound heterozygosity).

To determine whether certain gene networks were over-represented, two online
bioinformatics tools were used. First, STRING[38] was used to investigate experimental
and predicted protein-protein and genetic interactions, and clustering of RP genes was
demonstrated when the highest stringency filter was applied. In addition, PANTHER[37]
was employed to identify potential enrichment of genes by ontology classification.
Applying Fisher's exact test and false discovery rate corrections, RPs were the most
enriched class when compared to the reference proteome, including data annotated by
protein class (5.24-fold, p>0.0028), and cellular component (7.27-fold, p=0.011).

Generation of hPSC-VCMs

Id1 overexpressing hPSCs ([32], derived from [36]) were dissociated with 0.5 mM
EDTA (ThermoFisher Scientific) in PBS without $CaCl_2$ and $MgCl_2$ (Corning) for 7 min at
room temperature. hPSC were resuspended in mTeSR-1 media (StemCell
Technologies) supplemented with 2 µM Thiazovivin (StemCell Technologies) and plated
in a Matrigel-coated 12-well plate at a density of 3 x 10^5 cells per well. After 24 hours
after passage, cells were fed daily with mTeSR-1 media (without Thiazovivin) for 3-5
days until they reached ≥ 90% confluence to begin differentiation. hPSC-VCMs were
differentiated as previously described [36]. At day 0, cells were treated with 6 µM
CHIR99021 (Selleck Chemicals) in S12 media [95]. for 48 hours. At day 2, cells were
treated with 2 µM Wnt-C59 (Selleck Chemicals), an inhibitor of WNT pathway, in S12
media. 48 hours later (at day 4), S12 media is fully changed. At day 5, cells were
dissociated with TrypLE Express (Gibco) for 2 min and blocked with RPMI (Gibco)
supplemented with 10% FBS (Omega Scientific). Cells were resuspended in S12 media
supplemented with 4 mg/L Recombinant Human Insulin (Gibco) (S12+ media) and 2 µM
Thiazovivin and plated onto a Matrigel-coated 12-well plate at a density of 9 x 10^5 cells
per well. S12+ media was changed at day 8 and replaced at day 10 with RPMI (Gibco)
media supplemented with 213 µg/µL L-ascorbic acid (Sigma), 500 mg/L BSA-FV

(Gibco), 0.5 mM L-carnitine (Sigma) and 8 g/L AlbuMAX Lipid-Rich BSA (Gibco; CM

media). Typically, hPSC-ACMs start to beat around day 10. At day 15, cells were

purified with lactate media (RPMI without glucose, 213 µg/µL L-ascorbic acid, 500 mg/L

BSA-FV and 8 mM Sodium-DL-Lactate (Sigma), for 4 days. At day 19, media was

replaced with CM media.

siRNA transfection, proliferation assay and immunostaining in hPSC-VCMs

At day 25 of differentiation, hPSC-VCMs were dissociated with TrypLE Select

10X (Gibco), 10 min and neutralized with RPMI supplemented with 10% FBS. Cells

were resuspended in RPMI with 2% KOSR (Gibco) and 2% B27 50X with vitamin A (Life

Technologies) supplemented with 2 µM Thiazovivin and plated at a density of 5,000

cells/well in a Matrigel-coated 384-well plate. hPSC-VCMs were transfected with siRNA

(Dharmacon: ON-TARGETplus, custom RNAi cherry-pick libraries 0.1 nmol). For the

whole genome screening, siRNAs directed to 18,000 human genes were purchased

from the Genomic Center Facility at SBP at a final concentration of 25 nM using

lipofectamine RNAiMax (ThermoFisher) and opti-MEM (Gibco). 48 hours post-

transfection, cells were labelled with 10 µM EdU (ThermoFisher). After 24h of EdU

incubation, cells were fixed with 4% paraformaldehyde for 30 min and blocked in

blocking buffer (10% Horse Serum, 10% Gelatin and 0.5% Triton X-100) for 20 min.

EdU was detected according to protocol and cells were stained with cardiac specific

marker ACTN2 (A7811, Sigma, dilution 1/800), secondary antibody Alexa Fluor 568

(Invitrogen, 1/500) and DAPI (1/1000) in Blocking Buffer. Cells were imaged with

ImageXpress Micro XLS microscope (Molecular Devices) and custom algorithms were

used to quantify % of EdU+ ACTN1+ hPSC-VCMs and the number of ACTN1+ cells. To

quantify TP53 levels in hPSC-VCMs, cells were stained with Phospho-p53 (700439,

ThermoFisher, 1/500), counterstained with ACTN1 (anti-mouse A7811, Sigma, or anti-

rat ab50599, Abcam), and imaged and quantified with ImageXpress microscope. Whole

genome screening was performed in one-replicate. All the other siRNAs experiments

were performed in quadruplicates.

RNA-seq and data analysis

hPSCs and hPSC-derived CMs were transfected with 25nM final concentrations of
siRNA against RPS15A, RPL39 and with scrambled control siRNAs as above. Cells
were pelleted and resuspended in 500µl TRIzol reagent followed by total RNA
extraction. Library preparation and sequencing of the samples was done at La Jolla
Institute of Immunology (La Jolla, CA). FASTQ files were processed using nf-
core/rnaseq (version 21.03.0.edge [96]). Differential gene expression was determined
using R/DESeq2 [97] and GO term enrichment was done using gprofiler2[98]. Analysis
scripts can be downloaded at github.com/gvogler.

Proliferation assay in parent/proband iPSCs

hPSCs were dissociated as described previously and plated in a Matrigel-coated
384-well plate at a density of 3,000 cells per well. Cells were transfected with siRNA at
a final concentration of 25nM using lipofectamine RNAiMax and opti-MEM. After 3 days,
cells were labelled with 10 µM EdU for 1 hour. Cells were fixed with 4%
paraformaldehyde for 30 min and blocked in blocking buffer for 20 min. EdU was
detected according to the protocol and stained with stem cell specific marker OCT4
(P0082, Sigma, 1/500), secondary antibody Alexa Fluor 568 and DAPI in Blocking
Buffer. Cells were imaged with ImageXpress microscope and % of EdU+ cells and
number of OCT4+ cells were quantified.

Quantitative Real Time PCR (RT-qPCR) in parent/proband iPSCs and hPSC-CMs

Total RNA was extracted using TRIzol and chloroform. 1ug of RNA was
converted in cDNA using QuantiTect Reverse Transcription kit (Qiagen). qRT-PCR was
performed using SYBR green (Biorad). Human primers sequences for qRT-PCR were
obtained from Harvard Primer Bank: TP53 (Primer Bank ID: 371502118c1), CDKN1A
(Primer Bank ID: 310832423c1), CCNB1 (Primer Bank ID: 356582356c1), CCNB2
(Primer Bank ID: 332205979c1), CDK1 (Primer Bank ID: 281427275c1), MCM2 (Primer
Bank ID: 33356546c1), RPS15A (Primer Bank ID: 71772358c2). All values were
normalized to *GAPDH (Primer Bank ID: 378404907c1)*. At least 3 independent
biological replicates were performed for each experiment.

Statistical analysis

To determine any statistical significance between experimental and control groups in hPSC-VCMs and iPSCs from parent/proband trio, we calculated two-sided p values with Student's t-test using GraphPad Prism 8.1.2 software.

Drosophila heart function studies

Drosophila orthologs were determined using the DIOPT database [99], and fly stocks were obtained from the Vienna Drosophila Resource Center (VDRC) stock center or Bloomington Drosophila Stock Center (BDSC) as indicated in the key source table. For *in vivo* functional heart analysis, we developed a high-throughput method based on genetically modified flies with cardiomyocyte-specific RFP fluorescence (Klassen et al.). The reporter line by itself or combined with the heart-specific $Hand^{4.2}$-Gal4 driver (including all cardioblasts/cardiomyocytes, pericardial cells and wing hearts throughout development starting at post-mitotic, mid-embryonic stages through adulthood [100-102] was crossed to UAS-lines or mutant flies. For interaction studies a fly line harboring the fluorescent reporter, $Hand^{4.2}$-Gal4 driver and a Deficiency for RpS15Aa was generated. Adult progeny flies were immobilized and exposed to fluorescence light to record 5 sec high frame rate movies of the beating heart. Movies were analyzed by fully automated quantification of contractility and rhythmicity parameters of the heart [103]. Semi-intact adult fly hearts were filmed and analyzed according to standard protocol [26, 104].

Immunostainings of the fly heart

The immunostaining of fly adult hearts was performed as described previously [105]. In short, adult flies were dissected in a semi-intact fashion to expose the heart according to protocol [26, 106]. Myofibrils were relaxed using 10mM EGTA followed by fixation in 4% formaldehyde for 15 min. Hearts were washed with PBS + Triton (PBT; 0.03 % triton X-100) and stained using Alexa 647 phalloidin (Life Technologies) 2h at room temperature (RT). For Mhc labelling, hearts were stained using anti-Mhc antibody (1:50, incubation over night at 4°C) and after three washes with PBT, secondary

antibody was applied for 2 h at RT. Hearts were washed with PBT three times and PBS

one time and mounted using ProLong Gold mountant with DAPI (Life Technologies).

Heart preparations were imaged with the Imager.Z1 with an Apotome (Carl Zeiss),

Hamamatsu Orca Flash 4.0 and ZEN imaging software (Carl Zeiss).

Zebrafish Husbandry

All zebrafish experiments were performed in accordance with protocols approved

by IACUC. Zebrafish were maintained under standard laboratory conditions at 28.5°C.

In addition to Oregon AB wild-type, the following transgenic lines were used:

Tg(myl7:EGFP)^{twu277} [107] and *Tg(myl7:H2A-mCherry)^{sd12}* [108].

In zebrafish, gene expression was manipulated using standard microinjection of

morpholino (MO) antisense oligonucleotides [109]. In addition, we performed targeted

mutagenesis using CRISPR/Cas9 genome editing[110-112], to create insertion/deletion

(INDEL) mutations in relevant ribosomal genes (F0). Subsequently, zebrafish were

raised to 72 hours post fertilization (hpf), immobilized in low melt agarose and the hearts

were filmed and analyzed according to standard protocol[26].

MO sequence information:

All MOs were purchased from Gene Tools, LLC, synthesized at 300nmol, except

zebrafish p53 oligos at 100nmol.

Zebrafish *rpl13* 5'-UTR MO: TTGTTCACTCCGTCCTTAGCGGAAA

Zebrafish *rps15a* 5'-UTR MO: CGCACCATGATGCCAGTTCTGCAAT

Zebrafish *rpl39* 5'-UTR MO: GGATCGCAATCCGTTCACCACTATG

Zebrafish p53 MO: GCGCCATTGCTTTGCAAGAATTG

Zebrafish SOHA (Semi-automated Optical Heartbeat Analysis)

Larval zebrafish (72 hpf) were immobilized in a small amount of low melt agarose

(1.5%) and submerged in conditioned water. Beating hearts were imaged with direct

immersion optics and a digital high-speed camera (up to 200 frame/sec, Hamamatsu

Orca Flash) to record 30 seconds movies; images were captured using HC Image
(Hamamatsu Corp.). Cardiac function was analyzed from these high-speed movies
using semi-automatic optical heartbeat analysis software[26, 113], which for zebrafish
quantifies heart period (R-R interval), cardiac rhythmicity, as well as chamber size and
fractional area change. All hearts were imaged at room temperature (20-21°C).
Statistical analyses were performed using Prism software (Graphpad). Significance was
determined using two-tailed, unpaired student t-test or one-way ANOVA and Dunnett's
multiple comparisons post hoc test as appropriate.

Zebrafish Cardiomyocyte Cell Counts and Cardiac immunofluorescent imaging

To count cardiomyocytes, we used the expression of H2AmCherry in the nuclei
(*Tg(myl7:H2A-mCherry*)[108] to qualify as an individual cell, performed the "Spot"
function in Imaris to distinguish individual cells in reconstructions of confocal z-
stacks.[114, 115] To compare data sets, we used Prism software (GraphPad) to
perform Student's t-test with two-tail distribution. Graphs display mean and standard
deviation for each data set.

Whole-mount immunofluorescence was performed as previously described[17,
114-116] (see also key resources table). Confocal imaging was performed on an LSM
710 confocal microscope (Zeiss, Germany) with a 40x water objective. Exported z-
stacks were processed with Imaris software (Bitplane), Zeiss Zen, and Adobe Creative
Suite software (Photoshop and Illustrator 2020). All confocal images shown are
projection views of partial reconstructions from multiple z-stack slices, except where
noted that images are views of a single slice.

Zebrafish CRISPR/Cas9 experiments

Detailed steps were previously described[117] and we followed IDT manufacture
instruction for Complexes preparation. crRNA:tracrRNA Duplex Preparation: Target-
specific Alt-R® crRNA (sequence information see below) and common Alt-R®
tracrRNA were synthesized by IDT and each RNA was dissolved in duplex buffer (IDT)
as 100 µM stock solution. Stock solutions were stored at -20°C. To prepare the
crRNA:tracrRNA duplex, equal volumes of 100 µM Alt-R® crRNA and 100µM Alt-R®

tracrRNA stock solutions were mixed together and annealed by heating followed by
gradual cooling to room temperature by manufacture instruction: 95°C, 5 min on PCR
machine; cool to 25°C; cool to 4°C rapidly on ice. The 50 µM crRNA:tracrRNA duplex
stock solution was stored at -20°C. Preparation of crRNA:tracrRNA:Cas9 RNP
Complexes: Cas9 protein (Alt-R® S.p. Cas9 nuclease, v.3, IDT) was adjusted to 25 µM
stock solution in 20mM HEPES-NaOH (pH 7.5), 350 mM KCl, 20% glycerol, dispensed
as 8 ul aliquots, and stored at -80°C. 25µM crRNA:tracrRNA duplex was produced by
mixing equal volumes of 50 µM crRNA:tracrRNA duplex stock and duplex buffer (IDT).
We used 5 µM RNP complex. To generate 5µM crRNA:tracrRNA:Cas9 RNP complexes:
1 µl 25 µM crRNA:tracrRNA duplex was mixed with 1 µl 25 µM Cas9 stock, 2 µl H2O,
and 1 µl 0.25% phenol red solution. Prior to microinjection, the RNP complex solution
was incubated at 37°C, 5 min and then placed at room temperature. Approximately one
nanoliter of 5 µM RNP complex was injected into the cytoplasm of one-cell stage
embryos to generate F0 larva.

IDT crRNA sequence information:
All crRNAs were purchased from Integrated DNA Technologies, Inc., synthesized
at 2 nmol with standard desalting condition.

Dr.Cas9.RPS15A.1.AC: /AltR1/rUrU rGrUrU rGrUrC rArArU rCrUrC rArCrA rGrGrG
rGrUrU rUrUrA rGrArG rCrUrA rUrGrC rU/AltR2/

Dr.Cas9.RPS15A.1.AB: /AltR1/rGrC rGrUrA rCrUrA rUrGrA rCrUrU rUrArG rArGrC
rGrUrU rUrUrA rGrArG rCrUrA rUrGrC rU/AltR2/

Dr.Cas9.RPS17.1.AC:
/AltR1/rUrGrArCrUrUrCrCrArCrArUrUrArArCrArArGrCrGrUrUrUrUrArGrArGrCrUrArUrG
rCrU/AltR2/

Dr.Cas9.RPS28.1.AA:
/AltR1/rCrUrGrGrGrArArGrArArCrUrGrGrCrUrCrCrArGrUrUrUrUrArGrArGrCrUrArUr
GrCrU/AltR2/

Competing interests: None.

Table 1: Table 1 – Patients from poor outcome families carrying variants in ribosomal genes. Abbrevations: MAF – major allele frequency; TFBS – transcription factor binding site; n.t. – not tested; ASD – atrial septal defect; PLE - Protein-losing enteropathy; RV – right ventricle; RVEF – right ventricular ejection fraction; RVEDP - right ventricular end diastolic pressure

Figure 1: Whole Genome siRNA Screen identified Ribosomal proteins as agonists of cardiomyocyte proliferation. (A) High-throughput iPSC-derived CM proliferation screen overview. **(B)** Screen result showing normalized % EdU+ CMs (X-axis) and relative total number of CMs (Y-axis) upon knockdown of genome-wide siRNAs (18,055 siRNAs). siRNAs for RPL and RPS genes highlighted in red. **(C)** Representative immunofluorescence images of proliferation (EdU incorporation, green, CM marker ACTN2, red) of induced hPSC-CMs upon *TP53* and *RPS14* knockdown. Insets: nuclei (DAPI) **(D)** Gene ontology enrichment analysis for WGS hits (BP, biological process; FDR-corrected analysis using gprofiler2). (**E**) Overview of hits corresponding to top 4 non-redundant BP categories.

Figure 2: Ribosomal gene mutations found in HLHS families. (A) Gene prioritization scheme of 25 poor-outcome HLHS trios. **(B)** Testing 292 HLHS candidate genes from all poor-outcome families in CMs identified RPs as major regulators of hPSC-CM proliferation (Normalized fraction of ACTN2+/EdU+ cells). **(C)** Pedigree of the extended 75H family showing shared (co-segregating) variants between HLHS proband (black square) and distance cousin with CHD (half-filled circle). (**D**) Prioritized candidate genes from the 75H family and relative hPSC-CM proliferation capacity upon KD. **(E)** Representative immunofluorescence images of proliferation (EdU incorporation, green; CM marker ACTN2, red) of induced hPSC-CMs upon siRPS15A knockdown. **(F)** Heart-specific KD of *RpS15Aa* in *Drosophila* adult hearts cause loss of heart tissue and is fully penetrant. **(G)** Representative immunofluorescence images of control and *RpS15Aa*-RNAi shows partial heart loss (Myosin heavy chain, Mhc, red; heart tissue-reporter, green). **(H)** CRISPR-mediated loss of *rps15a* in F_0 larval zebrafish hearts causes

decrease in CM number. **(I)** Representative immunofluorescence of hearts and whole-
mount images of control and *rps15a*-CRISPR F_0 larval hearts (CM nuclei reporter, red).

Figure 3*:* **Loss of ribosomal gene function in CMs invokes TP53-stress response**.
(A) RNA sequencing of hPSC-CMs following siRNA-treatment for *RPL39* and *RPS15A*
shows both, convergent and divergent transcriptomic response. **(B)** GO term analysis of
differentially expressed genes following RP KD shows TP53-mediated response,
including upregulation of *CDKN1A*. **(C, D)** CDKN1A is highly upregulated in CMs
following *siRPS15A* treatment. **(E, F)** Reduced CM proliferation upon *RPS15A* KD is
mediated by *CDKN1A*/*TP53* and can be rescued upon their co-KD. **(G, H)** Larval
zebrafish CM number is reduced by morpholino-treatment for rps15a and can be
attenuated by P53 morpholino co-injection. Control and morphant (MO) hearts of 72 hpf
zebrafish larva stained with *Tg(myl7:EGFP)* and *Tg(myl7:H2A-mCherry)*. Note that
smaller heart with aberrant looping by *rps15a* MO is partially reversed by *p53* co-KD.
Student's t-test, *$p<0.05$, **$p<0.01$, ***$p<0.001$, ****$p<0.0001$**.

Figure 4*:* **Rescue of *RpS15Aa* KD-mediated heart tube loss in Drosophila by**
YAP/yorkie overexpression depending on its co-factor TEAD/scalloped. (A)
Representative images of RFP expressing fly hearts. RpS15Aa KD-mediated heart tube
loss can be partially rescued by overexpression of *yorkie* (*RpS15Aa* RNAi + *yorkie* OE)
and KD of *myc* (RpS15Aa RNAi + *myc* KD). The rescue by *yki* OE depends on its co-
factor *sd*. Flies were raised at 25 °C. **(B)** Quantification of events presented as a
percentage of flies exhibiting whole heart tube versus partial heart loss (defined as 25-
75% heart tube length compared to wildtype) or no heart tube. Statistics: Fisher's exact
test, *$p<0.05$. **(C)** Quantification of events presented as a percentage of flies exhibiting
anterior part of the heart (heart in segment A1-A3) compared to flies lacking anterior
part. One-week old flies were quantified. Statistics: Chi-square test, *$p<0.05$, **$p<0.005$,
***$p<0.001$**. (D)** Proposed signaling cascade underlying cardiac growth, proliferation and
differentiation impairment following ribosomal stress (adapted from Baker et al., 2019).

Figure 5: *RPS15A* genetically interacts with cardiac transcription factors. (A) The majority of cardiac transcription factors do not impact CM proliferation, with the exception of e.g. HES4 and HOPX. **(B)** *TBX5* genetically interacts with *RPS15A* and *RPL39*. *siTBX5* does not impact CM proliferation at 0.5, 1, 1.5 or 2nM si-concentration, and neither do *siRPS15A* and *siRPL39* alone at 0.5nM. CM proliferation is reduced in siRP backgrounds with increased titration of si*TBX5*. Two-way ANOVA for si*TBX5* dosage, RP-knockdown and their interaction. **(C)** Representative fly heart segment (A4) from control flies, heterozygous mutants (*tin*$^{346/+}$, *pnr*$^{VX6/+}$, *Doc*$^{Df/-}$, *Df(RpS15Aa)* $^{+/-}$) and transheterozygous mutants. *tin*$^{+/-}$ = *tin*^{346}/+, pnr$^{+/-}$ = *Df(pnr)*/+ , Doc$^{+/-}$ = *Df(DocA)*/+. Note the deformation and myofibrillar disorganization in the transheterozygous mutants. **(D)** Quantification of adult *Drosophila* heart defects and genetic interaction. - Statistics: Fisher's exact test on absolute numbers testing *normal* vs. *severely deformed* hearts. *p<0.05, **p<0.005, ***p<0.001.

Figure 6: RP-dependent cardiac-specific regulation of cell proliferation. (A) Schematic illustrating approach to identify novel RP-dependent and cardiac-specific HLHS-associated gene network controlling CM proliferation. **(B)** Heatmap showing differential expression (hiPSC-CMs vs hiPSCs) of genes regulating CM proliferation. **(C)** Histogram showing effect of cardiac-specific and HLHS-associated genes on CM proliferation. **(D)** Visualization of RP-dependent and cardiac-specific HLHS-associated gene network (GeneMania). HLHS families. **(E)** Table of HLHS families harboring rare and damaging variant in RP-dependent and cardiac-specific genes. **(F)** Histogram showing lack of effect of siEWSR1 on OCT4+ hiPSCs. **(G)** Representative images of OCT4+ cells in siControl and siEWSR1. **(H)** Histogram showing that siEWSR1 increases the % of CDKN1A+ CMs as compared to siControl. **(I)** Histogram showing that siEWSR1 concomitantly decreases the % of EdU+ CMs as compared to siControl. **(J)** Representative images showing immunostaining for CDKN1A (white), EdU (green) and ACTN2 (Red) in siEWSR1 an siControl condition. **(K)** Pathway reconstruction of cardiac and RP-dependent regulation of CM proliferation by HLHS-associated genes. Chi-square test, *p<0.05, **p<0.005, ***p<0.001

Figure 7: Model for RP-dependent involvement in HLHS-associated phenotypes.
Schematic showing that combined prioritization and unbiased screening led to the
identification of a novel HLHS-associated gene network regulating CM proliferation as
potential disease-causing mechanism.

Supplemental Figure 1: (A, B) Confirmatory siRNA screening for all RP genes
confirms critical role for RPs in CM proliferation. (**C, D**) KD of RPs reduces proliferation
in human fibroblasts.

Supplemental Figure 2: Model organism phenotypes caused by loss of RP genes.
(A) *Drosophila c*ardiac phenotypes induced by loss of RP genes affected in HLHS
patients with poor outcome. Heart is visualized by RFP expression specifically in
cardiomyocytes (*R94C02*::tdTom). Knockdown is achieved by sustained Gal4/UAS
activity using *Hand*4.2-Gal4. **(B)** Wild-type zebrafish larva, *rps17* and *rps28* CRISPR
mutants and *rpl39* morphants at 72 hpf. *rpl39* morphants, injected with 1 ng MO in
lateral view, show mild edema. **(C)** Systolic surface area (SA) upon *rps17* and *rps28*
CRISPR, and Diastolic SA after *rpl39* MO in the atrium and ventricle of zebrafish hearts.
(D) Diastolic and **(E)** and Systolic Surface Area after rps15a CRISPR. Statistics: Mann-
Whitney test, *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$, ****$p < 0.0001$

Supplemental Figure 3: **(A, B)** Schematic indicating the location of RPS15A in the
ribosomal small subunit (40S). The HLHS-associated variant contains a G>A
substitution in the *RPS15A* promoter (−95 upstream of the transcription start site), which
is a region predicted (ENCODE) to be rich in TF binding sites. **(C-E)** Quantification of
total hPSC cell numbers of father's hPSC with and without KD of *RPS15A* **(D)** and
representative images (hPSC marked with OCT4 (red) and nuclei (DAPI, blue)) **(E)**.

Supplemental Figure 4: *rps15a* **zebrafish larval morphants show heart
dysfunction and reduction in cardiomyocyte number. (A)** Lateral view (head to the
right) of a wild-type control zebrafish larva (top) and a morphant (bottom) following

injection of 2 ng/µl *rps15a* morpholino (MO). The morphant exhibits near normal

body/tail but notable pericardial edema (arrowhead). **(B)** Control (left) and morphant

hearts (right) stained with Tg(*myl7:EGFP*) and Tg(*myl7:H2A-mCherry*). Note the smaller

heart with aberrant looping in morphant heart. **(C)** Total CM counts (mCherry+ cells) in

control and *rps15a* morphants shown in (B). **(D)** Fractional area change in control and

rps15a morphants. Student's t-test, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.

Supplemental Figure 5: Proliferation and heart function is regulated by RPS15A

via TP53 in CMs and zebrafish. (A, B) The number of *siRPS15A*-treated CMs is

strongly reduced, which can be attenuated by co-KD of *CDKN1A* or *TP53*. **(C,D)** Loss

of *rps15a* causes strong reduction in zebrafish heart contractility (measured by

Fractional Area Change, **C**) and heart period **(D)**, which can be rescued by co-KD of

p53 in both, zebrafish heart atrium and ventricle.

Supplemental Figure 6: Genetic interaction between *RpS15Aa/RPS15A* and

***cabeza/EWSR1* in Drosophila resulting in prolonged systolic intervals. (A, B)**

Dose-dependent inhibition of hPSC-CMs proliferation by RPS15A KD. **(C)** Diastolic

Diameter (DD), and Heart Period (HP) of 3-week-old female control and heterozygous

RpS15Aa deficient flies with or without additional heterozygous mutation in tinman,

pannier or Dorsocross. Statistics: Kruskal-Wallis, *p<0.05, **p<0.005, ***p<0.001,

****p<0.0001. Note, the prolonged HP in transheterozygous mutants for Df(RpS15Aa)

and tinman. **(D, E)** FAC, and HP of the atria and ventricles at 72 hpf in zebrafish

embryos injected with 0.5 ng rps15a and/or 1 ng nkx2.7 MOs (**E**) or 0.5 ng rps15a

and/or 0.5 ng tbx5 MOs (F**).** Note, that FAC and heart periods show synergistic genetic

interaction between rps15a and nkx2.7 and tbx5a. Statistics: 2-Way ANOVA, *p<0.05,

p<0.01, ****p<0.0001.(F)** Systolic intervals (SI) of 1-week-old adult flies upon heart-

specific knockdown of *cabeza* (*caz[32990]* or *caz[34839]* RNAi) using Hand[4.2]-Gal4 driver with

or without additional RpS15Aa heterozygosity (RpS15Aa[Df/+]) and age-matched controls.

Automated analysis of SI depicted as median with interquartile range obtained from 5s

high-frame-rate videos. Statistics: Kruskal-Wallis test, *p<0.05, **p<0.01, ***p<0.001.

Supplemental Table 1: Whole genome siRNA screen results table.

Supplemental Table 2: 292 filtered variants from poor-outcome HLHS probands.

MOI – mode of inheritance

Supplemental Table 3: Segregating variants of 75H proband.

Supplemental Table 4: Subset from all 292 genes that cause CM proliferation

defects and/or fly heart defects

Supplemental Tables 5-8: Differential gene expression lists for siRPL39 and

siRPS15A in hPSCs and CMs.

1003

1004   **Supplemental Table 9: 12 genes prioritized after RNAseq and WGS analysis.**

1005

1006

1007

1008

1009

1010

REFERENCES

1.	Gordon BM, Rodriguez S, Lee M, Chang R-K. Decreasing number of deaths of infants with hypoplastic left heart syndrome. The Journal of Pediatrics. 2008;153(3):354-8. doi: 10.1016/j.jpeds.2008.03.009.

2.	Reller MD, Strickland MJ, Riehle-Colarusso T, Mahle WT, Correa A. Prevalence of congenital heart defects in metropolitan Atlanta, 1998-2005. The Journal of Pediatrics. 2008;153(6):807-13. doi: 10.1016/j.jpeds.2008.05.059.

3.	Crucean A, Alqahtani A, Barron DJ, Brawn WJ, Richardson RV, O'Sullivan J, et al. Re-evaluation of hypoplastic left heart syndrome from a developmental and morphological perspective. Orphanet Journal of Rare Diseases. 2017;12(1):138. doi: 10.1186/s13023-017-0683-4.

4.	Konno Y, Toki T, Tandai S, Xu G, Wang R, Terui K, et al. Mutations in the ribosomal protein genes in Japanese patients with Diamond-Blackfan anemia. Haematologica. 2010;95(8):1293-9. doi: 10.3324/haematol.2009.020826.

5.	Agopian AJ, Goldmuntz E, Hakonarson H, Sewda A, Taylor D, Mitchell LE, et al. Genome-Wide Association Studies and Meta-Analyses for Congenital Heart Defects. Circulation Cardiovascular Genetics. 2017;10(3):e001449. doi: 10.1161/CIRCGENETICS.116.001449.

6.	Martin LJ, Pilipenko V, Benson DW. Role of Segregation for Variant Discovery in Multiplex Families Ascertained by Probands With Left Sided Cardiovascular Malformations. Frontiers in Genetics. 2018;9:729. doi: 10.3389/fgene.2018.00729.

7.	Theis JL, Hrstka SCL, Evans JM, O'Byrne MM, de Andrade M, O'Leary PW, et al. Compound heterozygous NOTCH1 mutations underlie impaired cardiogenesis in a patient with hypoplastic left heart syndrome. Human Genetics. 2015;134(9):1003-11. doi: 10.1007/s00439-015-1582-1.

8.	Elliott DA, Kirk EP, Yeoh T, Chandar S, McKenzie F, Taylor P, et al. Cardiac homeobox gene NKX2-5 mutations and congenital heart disease: associations with atrial septal defect and hypoplastic left heart syndrome. Journal of the American College of Cardiology. 2003;41(11):2072-6. doi: 10.1016/s0735-1097(03)00420-0.

9.	Theis JL, Zimmermann MT, Evans JM, Eckloff BW, Wieben ED, Qureshi MY, et al. Recessive MYH6 Mutations in Hypoplastic Left Heart With Reduced Ejection Fraction. Circulation Cardiovascular Genetics. 2015;8(4):564-71. doi: 10.1161/CIRCGENETICS.115.001070.

10.	Zanon A, Kalvakuri S, Rakovic A, Foco L, Guida M, Schwienbacher C, et al. SLP-2 interacts with Parkin in mitochondria and prevents mitochondrial dysfunction in Parkin-deficient human iPSC-derived neurons and Drosophila. Hum Mol Genet. 2017;26(13):2412-25. doi: 10.1093/hmg/ddx132. PubMed PMID: 28379402.

11.	Dasgupta C, Martinez AM, Zuppan CW, Shah MM, Bailey LL, Fletcher WH. Identification of connexin43 (alpha1) gap junction gene mutations in patients with hypoplastic left heart syndrome by denaturing gradient gel electrophoresis (DGGE). Mutation Research. 2001;479(1-2):173-86. doi: 10.1016/s0027-5107(01)00160-9.

12.	Yagi H, Liu X, Gabriel GC, Wu Y, Peterson K, Murray SA, et al. The Genetic Landscape of Hypoplastic Left Heart Syndrome. Pediatr Cardiol. 2018;39(6):1069-81. Epub 20180322. doi: 10.1007/s00246-018-1861-4. PubMed PMID: 29569026; PubMed Central PMCID: PMCPMC8565805.

13.   Grossfeld P, Ye M, Harvey R. Hypoplastic left heart syndrome: new genetic insights. J
Am Coll Cardiol. 2009;53(12):1072-4. doi: 10.1016/j.jacc.2008.12.024. PubMed PMID:
19298922.
14.   Miao Y, Tian L, Martin M, Paige SL, Galdos FX, Li J, et al. Intrinsic Endocardial
Defects Contribute to Hypoplastic Left Heart Syndrome. Cell Stem Cell. 2020;27(4):574-89.e8.
doi: 10.1016/j.stem.2020.07.015.
15.   Liu X, Yagi H, Saeed S, Bais AS, Gabriel GC, Chen Z, et al. The complex genetics of
hypoplastic left heart syndrome. Nature genetics. 2017;49(7):1152-9. doi: 10.1038/ng.3870.
16.   Gaber N, Gagliardi M, Patel P, Kinnear C, Zhang C, Chitayat D, et al. Fetal
reprogramming and senescence in hypoplastic left heart syndrome and in human pluripotent stem
cells during cardiac differentiation. The American Journal of Pathology. 2013;183(3):720-34.
doi: 10.1016/j.ajpath.2013.05.022.
17.   Theis JL, Vogler G, Missinato MA, Li X, Nielsen T, Zeng X-XI, et al. Patient-specific
genomics and cross-species functional analysis implicate LRP2 in hypoplastic left heart
syndrome. eLife. 2020;9:e59554. doi: 10.7554/eLife.59554.
18.   Bodmer R. The gene tinman is required for specification of the heart and visceral muscles
in Drosophila. Development (Cambridge, England). 1993;118(3):719-29.
19.   Bodmer R. Heart development in Drosophila and its relationship to vertebrates. Trends in
Cardiovascular Medicine. 1995;5(1):21-8. doi: 10.1016/1050-1738(94)00032-Q.
20.   Cripps RM, Olson EN. Control of cardiac development by an evolutionarily conserved
transcriptional network. Developmental Biology. 2002;246(1):14-28. doi:
10.1006/dbio.2002.0666.
21.   Bodmer R, Frasch M. Chapter 1.2 - Development and Aging of the Drosophila Heart. In:
Rosenthal N, Harvey RP, editors. Heart Development and Regeneration. Boston: Academic
Press; 2010. p. 47-86.
22.   Bier E, Bodmer R. Drosophila, an emerging model for cardiac disease. Gene.
2004;342(1):1-11. doi: 10.1016/j.gene.2004.07.018.
23.   Evans SM, Yelon D, Conlon FL, Kirby ML. Myocardial lineage development.
Circulation Research. 2010;107(12):1428-44. doi: 10.1161/CIRCRESAHA.110.227405.
24.   Bakkers J. Zebrafish as a model to study cardiac development and human cardiac disease.
Cardiovascular Research. 2011;91(2):279-88. doi: 10.1093/cvr/cvr098.
25.   Liu J, Stainier DYR. Zebrafish in the study of early cardiac development. Circulation
Research. 2012;110(6):870-4. doi: 10.1161/CIRCRESAHA.111.246504.
26.   Fink M, Callol-Massot C, Chu A, Ruiz-Lozano P, Izpisua Belmonte JC, Giles W, et al. A
new method for detection and quantification of heartbeat parameters in Drosophila, zebrafish,
and embryonic mouse hearts. BioTechniques. 2009;46(2):101-13. doi: 10.2144/000113078.
27.   Huang G-Y, Xie L-J, Linask KL, Zhang C, Zhao X-Q, Yang Y, et al. Evaluating the role
of connexin43 in congenital heart disease: Screening for mutations in patients with outflow tract
anomalies and the analysis of knock-in mouse models. Journal of Cardiovascular Disease
Research. 2011;2(4):206-12. doi: 10.4103/0975-3583.89804.
28.   Yu MS, Spiering S, Colas AR. Generation of First Heart Field-like Cardiac Progenitors
and Ventricular-like Cardiomyocytes from Human Pluripotent Stem Cells. JoVE (Journal of
Visualized Experiments). 2018;(136):e57688. doi: 10.3791/57688.
29.   Paige SL, Galdos FX, Lee S, Chin ET, Ranjbarvaziri S, Feyen DAM, et al. Patient-
Specific Induced Pluripotent Stem Cells Implicate Intrinsic Impaired Contractility in Hypoplastic

Left Heart Syndrome. Circulation. 2020;142(16):1605-8. doi: 10.1161/CIRCULATIONAHA.119.045317.

30.   Diez-Cunado M, Wei K, Bushway PJ, Maurya MR, Perera R, Subramaniam S, et al. miRNAs that Induce Human Cardiomyocyte Proliferation Converge on the Hippo Pathway. Cell Rep. 2018;23(7):2168-74. Epub 2018/05/17. doi: 10.1016/j.celrep.2018.04.049. PubMed PMID: 29768213; PubMed Central PMCID: PMCPMC6261450.

31.   Murphy SA, Miyamoto M, Kervadec A, Kannan S, Tampakakis E, Kambhampati S, et al. PGC1/PPAR drive cardiomyocyte maturation at single cell level via YAP1 and SF3B2. Nature communications. 2021;12(1):1648. Epub 2021/03/14. doi: 10.1038/s41467-021-21957-z. PubMed PMID: 33712605; PubMed Central PMCID: PMCPMC7955035.

32.   Cunningham TJ, Yu MS, McKeithan WL, Spiering S, Carrette F, Huang C-T, et al. Id genes are essential for early heart formation. Genes & Development. 2017;31(13):1325-38. doi: 10.1101/gad.300400.117.

33.   Zhang Z, Li M, Wang H, Agrawal S, Zhang R. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci U S A. 2003;100(20):11636-41. Epub 2003/09/18. doi: 10.1073/pnas.1934692100. PubMed PMID: 13130078; PubMed Central PMCID: PMCPMC208810.

34.   Yuan LL, Green A, David L, Dozier C, Recher C, Didier C, et al. Targeting CHK1 inhibits cell proliferation in FLT3-ITD positive acute myeloid leukemia. Leuk Res. 2014;38(11):1342-9. Epub 2014/10/05. doi: 10.1016/j.leukres.2014.08.020. PubMed PMID: 25281057.

35.   Xu X, Xiong X, Sun Y. The role of ribosomal proteins in the regulation of cell proliferation, tumorigenesis, and genomic integrity. Sci China Life Sci. 2016;59(7):656-72. Epub 2016/06/14. doi: 10.1007/s11427-016-0018-0. PubMed PMID: 27294833.

36.   Burridge PW, Holmström A, Wu JC. Chemically Defined Culture and Cardiomyocyte Differentiation of Human Pluripotent Stem Cells. Current Protocols in Human Genetics. 2015;87:21.3.1-.3.15. doi: 10.1002/0471142905.hg2103s87.

37.   Mi H, Muruganujan A, Ebert D, Huang X, Thomas PD. PANTHER version 14: more genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools. Nucleic Acids Research. 2019;47(D1):D419-D26. doi: 10.1093/nar/gky1038.

38.   Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Research. 2019;47(D1):D607-D13. doi: 10.1093/nar/gky1131.

39.   Brand AH, Perrimon N. Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development (Cambridge, England). 1993;118(2):401-15.

40.   Schroeder AM, Allahyari M, Vogler G, Missinato MA, Nielsen T, Yu MS, et al. Model system identification of novel congenital heart disease gene candidates: focus on RPL13. Human Molecular Genetics. 2019;28(23):3954-69. doi: 10.1093/hmg/ddz213.

41.   Fink M, Callol-Massot C, Chu A, Ruiz-Lozano P, Izpisua Belmonte JC, Giles W, et al. A new method for detection and quantification of heartbeat parameters in Drosophila, zebrafish, and embryonic mouse hearts. BioTechniques. 2009;46(2):101-13. doi: 10.2144/000113078. PubMed PMID: 19317655; PubMed Central PMCID: PMC2855226.

42. Uechi T, Nakajima Y, Nakao A, Torihara H, Chakraborty A, Inoue K, et al. Ribosomal
Protein Gene Knockdown Causes Developmental Defects in Zebrafish. PLOS ONE.
2006;1(1):e37. doi: 10.1371/journal.pone.0000037.
43. Ikeda F, Yoshida K, Toki T, Uechi T, Ishida S, Nakajima Y, et al. Exome sequencing
identified RPS15A as a novel causative gene for Diamond-Blackfan anemia. Haematologica.
2017;102(3):e93-e6. doi: 10.3324/haematol.2016.153932.
44. Miura GI, Yelon D. A Guide to Analysis of Cardiac Phenotypes in the Zebrafish Embryo.
Methods in Cell Biology. 2011;101:161-80. doi: 10.1016/B978-0-12-387036-0.00007-4.
45. Fischer M. Census and evaluation of p53 target genes. Oncogene. 2017;36(28):3943-56.
Epub 2017/03/14. doi: 10.1038/onc.2016.502. PubMed PMID: 28288132; PubMed Central
PMCID: PMCPMC5511239.
46. Robu ME, Larson JD, Nasevicius A, Beiraghi S, Brenner C, Farber SA, et al. p53
activation by knockdown technologies. PLoS genetics. 2007;3(5):e78. doi:
10.1371/journal.pgen.0030078.
47. Furth N, Aylon Y, Oren M. p53 shades of Hippo. Cell Death and Differentiation.
2018;25(1):81-92. doi: 10.1038/cdd.2017.163.
48. Baker NE, Kiparaki M, Khan C. A potential link between p53, cell competition and
ribosomopathy in mammals and in Drosophila. Developmental Biology. 2019;446(1):17-9. doi:
10.1016/j.ydbio.2018.11.018.
49. Ollmann M, Young LM, Di Como CJ, Karim F, Belvin M, Robertson S, et al. Drosophila
p53 is a structural and functional homolog of the tumor suppressor p53. Cell. 2000;101(1):91-
101. doi: 10.1016/S0092-8674(00)80626-1. PubMed PMID: 10778859.
50. Raj N, Bam R. Reciprocal Crosstalk Between YAP1/Hippo Pathway and the p53 Family
Proteins: Mechanisms and Outcomes in Cancer. Front Cell Dev Biol. 2019;7:159. Epub
20190809. doi: 10.3389/fcell.2019.00159. PubMed PMID: 31448276; PubMed Central PMCID:
PMCPMC6695833.
51. Monroe TO, Hill MC, Morikawa Y, Leach JP, Heallen T, Cao S, et al. YAP Partially
Reprograms Chromatin Accessibility to Directly Induce Adult Cardiogenesis In Vivo.
Developmental Cell. 2019;48(6):765-79.e7. doi: 10.1016/j.devcel.2019.01.017.
52. van Riggelen J, Yetil A, Felsher DW. MYC as a regulator of ribosome biogenesis and
protein synthesis. Nat Rev Cancer. 2010;10(4):301-9. doi: 10.1038/nrc2819. PubMed PMID:
20332779.
53. Kang J, Brajanovski N, Chan KT, Xuan J, Pearson RB, Sanij E. Ribosomal proteins and
human diseases: molecular mechanisms and targeted therapy. Signal Transduct Target Ther.
2021;6(1):323. Epub 2021/09/01. doi: 10.1038/s41392-021-00728-8. PubMed PMID: 34462428;
PubMed Central PMCID: PMCPMC8405630.
54. Bruneau BG, Logan M, Davis N, Levi T, Tabin CJ, Seidman JG, et al. Chamber-specific
cardiac expression of Tbx5 and heart defects in Holt-Oram syndrome. Dev Biol.
1999;211(1):100-8. doi: 10.1006/dbio.1999.9298. PubMed PMID: 10373308.
55. Qian L, Wythe JD, Liu J, Cartry J, Vogler G, Mohapatra B, et al. Tinman/Nkx2-5 acts via
miR-1 and upstream of Cdc42 to regulate heart function across species. J Cell Biol.
2011;193(7):1181-96. Epub 20110620. doi: 10.1083/jcb.201006114. PubMed PMID: 21690310;
PubMed Central PMCID: PMCPMC3216339.
56. Lee KH, Xu Q, Breitbart RE. A new tinman-related gene, nkx2.7, anticipates the
expression of nkx2.5 and nkx2.3 in zebrafish heart and pharyngeal endoderm. Developmental
Biology. 1996;180(2):722-31. doi: 10.1006/dbio.1996.0341.

57.   Targoff KL, Schell T, Yelon D. Nkx Genes Regulate Heart Tube Extension and Exert
Differential Effects on Ventricular and Atrial Cell Number. Developmental biology.
2008;322(2):314-21. doi: 10.1016/j.ydbio.2008.07.037.
58.   Tiu GC, Kerr CH, Forester CM, Krishnarao PS, Rosenblatt HD, Raj N, et al. A p53-
dependent translational program directs tissue-selective phenotypes in a model of
ribosomopathies. Developmental Cell. 2021;0(0). doi: 10.1016/j.devcel.2021.06.013.
59.   McGowan KA, Pang WW, Bhardwaj R, Perez MG, Pluvinage JV, Glader BE, et al.
Reduced ribosomal protein gene dosage and p53 activation in low-risk myelodysplastic
syndrome. Blood. 2011;118(13):3622-33. Epub 20110725. doi: 10.1182/blood-2010-11-318584.
PubMed PMID: 21788341; PubMed Central PMCID: PMCPMC3186336.
60.   Flucke U, van Noesel MM, Siozopoulou V, Creytens D, Tops BBJ, van Gorp JM, et al.
EWSR1-The Most Common Rearranged Gene in Soft Tissue Lesions, Which Also Occurs in
Different Bone Lesions: An Updated Review. Diagnostics (Basel). 2021;11(6). Epub 20210615.
doi: 10.3390/diagnostics11061093. PubMed PMID: 34203801; PubMed Central PMCID:
PMCPMC8232650.
61.   Vlachos A, Osorio DS, Atsidaftos E, Kang J, Lababidi ML, Seiden HS, et al. The
Increased Prevalence of Congenital Heart Disease (CHD) in Children with Diamond Blackfan
Anemia (DBA) Suggests Unrecognized DBA as a Cause of CHD in the General Population: A
Report of the Diamond Blackfan Anemia Registry. Circulation Genomic and precision medicine.
2018;11(5):e002044. doi: 10.1161/CIRCGENETICS.117.002044.
62.   Jin SC, Homsy J, Zaidi S, Lu Q, Morton S, DePalma SR, et al. Contribution of rare
inherited and de novo variants in 2,871 congenital heart disease probands. Nature genetics.
2017;49(11):1593-601. doi: 10.1038/ng.3970.
63.   Danilova N, Gazda HT. Ribosomopathies: how a common root can cause a tree of
pathologies. Disease Models & Mechanisms. 2015;8(9):1013-26. doi: 10.1242/dmm.020529.
64.   Boulon S, Westman BJ, Hutten S, Boisvert F-M, Lamond AI. The nucleolus under stress.
Molecular Cell. 2010;40(2):216-27. doi: 10.1016/j.molcel.2010.09.024.
65.   Yang K, Yang J, Yi J. Nucleolar Stress: hallmarks, sensing mechanism and diseases. Cell
Stress. 2018;2(6):125-40. doi: 10.15698/cst2018.06.139.
66.   Dai M-S, Zeng SX, Jin Y, Sun X-X, David L, Lu H. Ribosomal protein L23 activates p53
by inhibiting MDM2 function in response to ribosomal perturbation but not to translation
inhibition. Molecular and Cellular Biology. 2004;24(17):7654-68. doi:
10.1128/MCB.24.17.7654-7668.2004.
67.   Zhang Y, Lu H. Signaling to p53: ribosomal proteins find their way. Cancer cell.
2009;16(5):369-77. doi: 10.1016/j.ccr.2009.09.024.
68.   Men H, Cai H, Cheng Q, Zhou W, Wang X, Huang S, et al. The regulatory roles of p53
in cardiovascular health and disease. Cell Mol Life Sci. 2021;78(5):2001-18. Epub 20201111.
doi: 10.1007/s00018-020-03694-6. PubMed PMID: 33179140.
69.   Mak TW, Hauck L, Grothe D, Billia F. p53 regulates the cardiac transcriptome. Proc Natl
Acad Sci U S A. 2017;114(9):2331-6. Epub 20170213. doi: 10.1073/pnas.1621436114. PubMed
PMID: 28193895; PubMed Central PMCID: PMCPMC5338492.
70.   Deisenroth C, Zhang Y. The Ribosomal Protein-Mdm2-p53 Pathway and Energy
Metabolism. Genes & Cancer. 2011;2(4):392-403. doi: 10.1177/1947601911409737.
71.   Liu Y, Deisenroth C, Zhang Y. RP–MDM2–p53 Pathway: Linking Ribosomal
Biogenesis and Tumor Surveillance. Trends in cancer. 2016;2(4):191-204. doi:
10.1016/j.trecan.2016.03.002.

72.   Vassilev LT. MDM2 inhibitors for cancer therapy. Trends Mol Med. 2007;13(1):23-31. Epub 20061128. doi: 10.1016/j.molmed.2006.11.002. PubMed PMID: 17126603.

73.   Munisamy M, Mukherjee N, Thomas L, Pham AT, Shakeri A, Zhao Y, et al. Therapeutic opportunities in cancer therapy: targeting the p53-MDM2/MDMX interactions. Am J Cancer Res. 2021;11(12):5762-81. Epub 20211215. PubMed PMID: 35018225; PubMed Central PMCID: PMCPMC8727821.

74.   Cui Z, DiMario PJ. RNAi knockdown of Nopp140 induces Minute-like phenotypes in Drosophila. Molecular Biology of the Cell. 2007;18(6):2179-91. doi: 10.1091/mbc.e07-01-0074.

75.   James A, Cindass R, Mayer D, Terhoeve S, Mumphrey C, DiMario P. Nucleolar stress in Drosophila melanogaster: RNAi-mediated depletion of Nopp140. Nucleus (Austin, Tex). 2013;4(2):123-33. doi: 10.4161/nucl.23944.

76.   Destefanis F, Manara V, Bellosta P. Myc as a Regulator of Ribosome Biogenesis and Cell Competition: A Link to Cancer. International Journal of Molecular Sciences. 2020;21(11):4037. doi: 10.3390/ijms21114037.

77.   Morcelle C, Menoyo S, Morón-Duran FD, Tauler A, Kozma SC, Thomas G, et al. Oncogenic MYC Induces the Impaired Ribosome Biogenesis Checkpoint and Stabilizes p53 Independent of Increased Ribosome Content. Cancer Research. 2019;79(17):4348-59. doi: 10.1158/0008-5472.CAN-18-2718.

78.   Dai M-S, Sears R, Lu H. Feedback regulation of c-Myc by ribosomal protein L11. Cell Cycle (Georgetown, Tex). 2007;6(22):2735-41. doi: 10.4161/cc.6.22.4895.

79.   Barron DA, Kagey JD. The role of the Hippo pathway in human disease and tumorigenesis. Clinical and Translational Medicine. 2014;3:25. doi: 10.1186/2001-1326-3-25.

80.   Del Re DP. The hippo signaling pathway: implications for heart regeneration and disease. Clinical and Translational Medicine. 2014;3(1):27. doi: 10.1186/s40169-014-0027-0.

81.   Yu L, Daniels JP, Wu H, Wolf MJ. Cardiac hypertrophy induced by active Raf depends on Yorkie-mediated transcription. Sci Signal. 2015;8(362):ra13-ra. doi: 10.1126/scisignal.2005719.

82.   Wang J, Liu S, Heallen T, Martin JF. The Hippo pathway in the heart: pivotal roles in development, disease, and regeneration. Nature Reviews Cardiology. 2018;15(11):672-84. doi: 10.1038/s41569-018-0063-3.

83.   Xiao Y, Leach J, Wang J, Martin JF. Hippo/Yap Signaling in Cardiac Development and Regeneration. Current Treatment Options in Cardiovascular Medicine. 2016;18(6):38. doi: 10.1007/s11936-016-0461-y.

84.   Kaya-Çopur A, Marchiano F, Hein MY, Alpern D, Russeil J, Luis NM, et al. The Hippo pathway controls myofibril assembly and muscle fiber growth by regulating sarcomeric gene expression. bioRxiv. 2020:2020.10.08.330951. doi: 10.1101/2020.10.08.330951.

85.   von Gise A, Lin Z, Schlegelmilch K, Honor LB, Pan GM, Buck JN, et al. YAP1, the nuclear target of Hippo signaling, stimulates heart growth through cardiomyocyte proliferation but not hypertrophy. Proceedings of the National Academy of Sciences of the United States of America. 2012;109(7):2394-9. doi: 10.1073/pnas.1116136109.

86.   Del Re DP, Yang Y, Nakano N, Cho J, Zhai P, Yamamoto T, et al. Yes-associated protein isoform 1 (Yap1) promotes cardiomyocyte survival and growth to protect against myocardial ischemic injury. The Journal of Biological Chemistry. 2013;288(6):3977-88. doi: 10.1074/jbc.M112.436311.

87.   Ye M, Coldren C, Liang X, Mattina T, Goldmuntz E, Benson DW, et al. Deletion of ETS-1, a gene in the Jacobsen syndrome critical region, causes ventricular septal defects and

abnormal ventricular morphology in mice. Hum Mol Genet. 2010;19(4):648-56. Epub 20091126. doi: 10.1093/hmg/ddp532. PubMed PMID: 19942620; PubMed Central PMCID: PMCPMC2807373.

88.   Kennedy L, Kaltenbrun E, Greco TM, Temple B, Herring LE, Cristea IM, et al. Formation of a TBX20-CASZ1 protein complex is protective against dilated cardiomyopathy and critical for cardiac homeostasis. PLoS Genet. 2017;13(9):e1007011. Epub 20170925. doi: 10.1371/journal.pgen.1007011. PubMed PMID: 28945738; PubMed Central PMCID: PMCPMC5629033.

89.   Barak Y, Hemberger M, Sucov HM. Phases and Mechanisms of Embryonic Cardiomyocyte Proliferation and Ventricular Wall Morphogenesis. Pediatr Cardiol. 2019;40(7):1359-66. Epub 20190724. doi: 10.1007/s00246-019-02164-6. PubMed PMID: 31342113; PubMed Central PMCID: PMCPMC6786952.

90.   Kathiriya IS, Rao KS, Iacono G, Devine WP, Blair AP, Hota SK, et al. Modeling Human TBX5 Haploinsufficiency Predicts Regulatory Networks for Congenital Heart Disease. Dev Cell. 2021;56(3):292-309 e9. Epub 20201214. doi: 10.1016/j.devcel.2020.11.020. PubMed PMID: 33321106; PubMed Central PMCID: PMCPMC7878434.

91.   Tanaka M, Yamaguchi S, Yamazaki Y, Kinoshita H, Kuwahara K, Nakao K, et al. Somatic chromosomal translocation between Ewsr1 and Fli1 loci leads to dilated cardiomyopathy in a mouse model. Sci Rep. 2015;5:7826. Epub 20150116. doi: 10.1038/srep07826. PubMed PMID: 25591392; PubMed Central PMCID: PMCPMC5379005.

92.   Ragni CV, Diguet N, Le Garrec JF, Novotova M, Resende TP, Pop S, et al. Amotl1 mediates sequestration of the Hippo effector Yap1 downstream of Fat4 to restrict heart growth. Nat Commun. 2017;8:14582. Epub 20170227. doi: 10.1038/ncomms14582. PubMed PMID: 28239148; PubMed Central PMCID: PMCPMC5333361.

93.   Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581(7809):434-43. doi: 10.1038/s41586-020-2308-7.

94.   Grodecká L, Kramárek M, Lockerová P, Kováčová T, Ravčuková B, Richterová R, et al. No major effect of the CDH1 c.2440-6C>G mutation on splicing detected in last exon-specific splicing minigene assay. Genes, Chromosomes and Cancer. 2014;53(9):798-801. doi: https://doi.org/10.1002/gcc.22186.

95.   Pei F, Jiang J, Bai S, Cao H, Tian L, Zhao Y, et al. Chemical-defined and albumin-free generation of human atrial and ventricular myocytes from human pluripotent stem cells. Stem Cell Research. 2017;19:94-103. doi: 10.1016/j.scr.2017.01.006.

96.   Ewels PA, Peltzer A, Fillinger S, Patel H, Alneberg J, Wilm A, et al. The nf-core framework for community-curated bioinformatics pipelines. Nat Biotechnol. 2020;38(3):276-8. doi: 10.1038/s41587-020-0439-x. PubMed PMID: 32055031.

97.   Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. doi: 10.1186/s13059-014-0550-8. PubMed PMID: 25516281; PubMed Central PMCID: PMCPMC4302049.

98.   Raudvere U, Kolberg L, Kuzmin I, Arak T, Adler P, Peterson H, et al. g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res. 2019;47(W1):W191-W8. doi: 10.1093/nar/gkz369. PubMed PMID: 31066453; PubMed Central PMCID: PMCPMC6602461.

99.   Hu Y, Flockhart I, Vinayagam A, Bergwitz C, Berger B, Perrimon N, et al. An integrative approach to ortholog prediction for disease-focused and other functional studies.

BMC Bioinformatics. 2011;12:357. Epub 20110831. doi: 10.1186/1471-2105-12-357. PubMed PMID: 21880147; PubMed Central PMCID: PMCPMC3179972.

100.   Han Z, Yi P, Li X, Olson EN. Hand, an evolutionarily conserved bHLH transcription factor required for Drosophila cardiogenesis and hematopoiesis. Development (Cambridge, England). 2006;133(6):1175-82. doi: 10.1242/dev.02285.

101.   Tögel M, Meyer H, Lehmacher C, Heinisch JJ, Pass G, Paululat A. The bHLH transcription factor hand is required for proper wing heart formation in Drosophila. Developmental Biology. 2013;381(2):446-59. doi: 10.1016/j.ydbio.2013.05.027.

102.   Hallier B, Hoffmann J, Roeder T, Tögel M, Meyer H, Paululat A. The bHLH Transcription Factor Hand Regulates the Expression of Genes Critical to Heart and Muscle Function in Drosophila melanogaster. PloS One. 2015;10(8):e0134204. doi: 10.1371/journal.pone.0134204.

103.   Vogler G. gvogler/FlyHearts-tdtK-Rscripts: First release of the R tdtK script. First ed: Zenodo; 2021.

104.   Cammarato A, Ocorr S, Ocorr K. Enhanced assessment of contractile dynamics in Drosophila hearts. Biotechniques. 2015;58(2):77-80. Epub 20150201. doi: 10.2144/000114255. PubMed PMID: 25652030.

105.   Alayari NN, Vogler G, Taghli-Lamallem O, Ocorr K, Bodmer R, Cammarato A. Fluorescent labeling of Drosophila heart structures. Journal of Visualized Experiments: JoVE. 2009;(32). doi: 10.3791/1423.

106.   Ocorr K, Vogler G, Bodmer R. Methods to assess Drosophila heart development, function and aging. Methods (San Diego, Calif). 2014;68(1):265-72. doi: 10.1016/j.ymeth.2014.03.031.

107.   Huang C-J, Tu C-T, Hsiao C-D, Hsieh F-J, Tsai H-J. Germ-line transmission of a myocardium-specific GFP transgene reveals critical regulatory elements in the cardiac myosin light chain 2 promoter of zebrafish. Developmental Dynamics: An Official Publication of the American Association of Anatomists. 2003;228(1):30-40. doi: 10.1002/dvdy.10356.

108.   Schumacher JA, Bloomekatz J, Garavito-Aguilar ZV, Yelon D. tal1 Regulates the formation of intercellular junctions and the maintenance of identity in the endocardium. Developmental Biology. 2013;383(2):214-26. doi: 10.1016/j.ydbio.2013.09.019.

109.   Westerfield M. The zebrafish book: A guide for the laboratory use of zebrafish (Brachydanio rerio). 1993 ed: M. W, editor: University of Oregon Press; 1993.

110.   Talbot JC, Amacher SL. A streamlined CRISPR pipeline to reliably generate zebrafish frameshifting alleles. Zebrafish. 2014;11(6):583-5. doi: 10.1089/zeb.2014.1047.

111.   Gagnon JA, Valen E, Thyme SB, Huang P, Akhmetova L, Ahkmetova L, et al. Efficient mutagenesis by Cas9 protein-mediated oligonucleotide insertion and large-scale assessment of single-guide RNAs. PloS One. 2014;9(5):e98186. doi: 10.1371/journal.pone.0098186.

112.   Irion U, Krauss J, Nüsslein-Volhard C. Precise and efficient genome editing in zebrafish using the CRISPR/Cas9 system. Development (Cambridge, England). 2014;141(24):4827-30. doi: 10.1242/dev.115584.

113.   Ocorr K, Fink M, Cammarato A, Bernstein SI, Bodmer R. Semi-automated Optical Heartbeat Analysis of Small Hearts. Journal of Visualized Experiments : JoVE. 2009;(31). doi: 10.3791/1435.

114.   Zeng X-XI, Yelon D. Cadm4 restricts the production of cardiac outflow tract progenitor cells. Cell Reports. 2014;7(4):951-60. doi: 10.1016/j.celrep.2014.04.013.

115.   Pradhan A, Zeng X-XI, Sidhwani P, Marques SR, George V, Targoff KL, et al. FGF
signaling enforces cardiac chamber identity in the developing ventricle. Development.
2017;144(7):1328-38. doi: 10.1242/dev.143719.

116.   Alexander J, Stainier DY, Yelon D. Screening mosaic F1 females for mutations affecting
zebrafish heart induction and patterning. Developmental Genetics. 1998;22(3):288-99. doi:
10.1002/(SICI)1520-6408(1998)22:3<288::AID-DVG10>3.0.CO;2-2.

117.   Hoshijima K, Jurynec MJ, Klatt Shaw D, Jacobi AM, Behlke MA, Grunwald DJ. Highly
Efficient CRISPR-Cas9-Based Methods for Generating Deletion Mutations and F0 Embryos that
Lack Gene Function in Zebrafish. Developmental Cell. 2019;51(5):645-57.e4. doi:
10.1016/j.devcel.2019.10.004.

1383

Figure 1

A

Day 25 hPSC-CMs

18,055 siRNAs tested → 48h → **EdU addition** → 24h → Day 28

Automated Image Analysis

EdU assay
ACTN1
DAPI

High-throughput Fluorescence Microscopy

B

- RPL/RPS genes (red)
- all siRNAs (green)

Relative hPSC-CM numbers (CM) vs EdU

Relative EdU+, ACTN2+ CMs

CDKN1A, TP53, MDM2, CHEK1, RPS14

153 hits

C

siControl, siCDKN1A, siTP53, siRPS14

ACTN2, EdU, DAPI

D

Enrichment of 153 top hits (Biological Process, BP)

Term	P value	Genes
nuclear-transcribed mRNA catabolic process	1.94e-43	41
protein targeting to ER	3.17e-56	41
establishment of protein localization to organelle	9.35e-30	43
Ribosome	1.78e-46	42
signal transduction by p53 class mediator	4.87e-02	8
positive regulation of vascular endothelial growth factor signaling pathway	3.20e-02	2
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	3.73e-02	3
regulation of signal transduction by p53 class mediator	6.05e-03	8
ribosomal small subunit assembly	2.09e-07	6
ribosomal large subunit assembly	2.03e-06	6
negative regulation of smoothened signaling pathway	4.71e-02	3

E

Genes — **GO (BP)**

RIBOSOME

NEGATIVE REGULATION OF SMOOTHENED SIGNALING

POSITIVE REGULATION OF VEGF SIGNALING

SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR

% EdU+ CM 0 — 0.5

Figure 2

A
Variant Filter: MAF<1%, Missense, Loss of Function, Canonical Splice, Promotor
Gene Filter: Upper Quartile Fetal Heart Expression
Inheritance Filter: De novo (26), Compound heterozygous (196), X-linked recessive (83), Homozygous recessive (12)
HLHS trios with poor outcome (n = 25)
Enrichment analysis (292 unique genes)
Protein class
Ribosomal protein (5.24-fold, p=0.0028)
Cellular component
Large Ribosomal Subunit (7.27-fold, p=0.011)

B –log(P-Value) vs Normalized EdU+ CMs. RPS28, RPS15, RPS17, RPL26L1, RPL39, RPL36A–HNRNPH2, RPL13A, RPL36A, RPL10, RPL3L

C 75H Family
affected (HLHS), BAV, unaffected, unknown
co-segregating variants (incl. *RPS15A*)

D Normalized % of ACTN2+/EdU+ Cells: siCtrl, siRPS15A, siGDE1, siWDR33, siNADK2, siACSF2, siRSL1D1

E hPSC-CMs
siControl
siRPS15A
50 bm
ACTN2 EdU DAPI

F % (Flies): partial heart, whole heart, n=10/condition
control, RpS15Aa KD

G *Drosophila*
Control
RpS15Aa RNAi
100 µm
anti-Mhc, R94C02::tdTomato

H number of CMs
Whole heart, Ventricle, Atrium
control, rps15a CRISPR

I Zebrafish
72 hpf
V, A
Control
30 um
rps15a CRISPR
myl7::H2A-mCherry

Figure 3

Figure 4

Figure 5

Supp. Figure 1

Supp. Figure 2

A

Small ribosomal
Subunit

RPS15A

Promoter Region

| Position | -95 |
| Mutation | G>A |

Mutation type   TF binding Loss
(Encode TFBS)

RPS15A

TSS

B

Gene Symbol	Consequence	Variant	MAF%	CADD	TFs
RPS15A	Regulatory	c.-95G>A	0.662		MAX; SRF; GTF2B; BRCA1; CHD2; NR2C2; ETS1; YY1; RXRA; HEY1; POLR2A; SIN3A; MYC; E2F1; E2F4; ZNF143; EGR1; ZNF263; TBP; SETDB1; STAT1; PAX5; ZBTB33; GTF2F1; POU2F2; NFKB1; FOSL2; REST; ELF1; Hltf; SP1; IRF1; BCL3; TAF7; TAF1

C

siRPS15A

*Father
iPSC*

3 days

*Quantification of
% of OCT4+ Cells*

iPSC

D

****

Normalized OCT4+
Cell Number

Father

Father +
siRPS15A

E

Father

Father + siRPS15A

OCT4 DAPI

Supp. Figure 4

A

72hpf

Control

72hpf

rps15a MO

B

72hpf

Control

rps15a MO

Tg(myl:EGFP) / *Tg(myl7::H2A-mCherry)*

C

number of CMs

Whole heart

****

Ventricle

****

Atrium

****

Control rps15a MO Control rps15a MO Control rps15a MO

D

FAC [%]

Atrium   Ventricle

**   **

Control rps15a MO Control rps15a MO